INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338394, 'Fluvoxamine', 'Eluxadoline', 'Moderate', 'It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.', NULL, 'As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.', NULL, 'As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338395, 'Fluvoxamine', 'Methadone', 'Moderate', 'Coadministration with fluvoxamine may increase the serum concentrations of methadone. The mechanism is fluvoxamine inhibition of methadone metabolism via CYP450 2C9 and 3A4.', NULL, 'Caution is advised if methadone must be used in combination with fluvoxamine.', NULL, 'Caution is advised if methadone must be used in combination with fluvoxamine. Pharmacologic response to methadone should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of fluvoxamine in patients who are stabilized on their methadone regimen. Patients should be advised to report excessive drowsiness, nausea, or asthenia to their doctor, and to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338396, 'Fluvoxamine', 'Prochlorperazine', 'Moderate', 'Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', NULL, 'During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338397, 'Fluvoxamine', 'Spironolactone', 'Moderate', 'Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.', NULL, 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.', NULL, 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338398, 'Folic acid', 'Capecitabine', 'Major', 'Coadministration with folate therapy may potentiate the pharmacologic effects of 5-fluorouracil (5-FU). The exact mechanism of interaction is unknown. Although enhancement of 5-FU cytotoxicity may be used to advantage in some cancer patients, increased toxicity should also be considered. Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.', NULL, 'Caution is advised if 5-FU or any of its prodrugs (e.', NULL, 'Caution is advised if 5-FU or any of its prodrugs (e.g., capecitabine, tegafur) are prescribed in combination with leucovorin. A lower dosage of 5-FU or the prodrug may be required. Therapy with leucovorin and fluorouracil should not be initiated or continued in patients with symptoms of gastrointestinal toxicity until such symptoms have resolved. Closely monitor patients with diarrhea until it resolves. Monitor for other potential toxicities of 5-FU such as neutropenia, thrombocytopenia, stomatitis, cutaneous reactions, and neuropathy. Patients should be instructed to avoid taking folic acid supplementation or multivitamin preparations containing folic acid without first speaking with their physician.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338399, 'Folic acid', 'Carbamazepine', 'Moderate', 'Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.', NULL, 'Caution is advised when folate therapy is coadministered with anticonvulsants.', NULL, 'Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338400, 'Folic acid', 'Cholestyramine', 'Moderate', 'INTERVAL: Concurrent administration with cholestyramine or colestipol may interfere with the absorption of some hydro-soluble vitamins such as folic acid.', NULL, 'Patients on prolonged cholestyramine or colestipol therapy should take folic acid supplements at least 1 hour before or 4 to 6 hours after receiving cholestyramine or colestipol.', NULL, 'Patients on prolonged cholestyramine or colestipol therapy should take folic acid supplements at least 1 hour before or 4 to 6 hours after receiving cholestyramine or colestipol.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338401, 'Folic acid', 'Colestipol', 'Moderate', 'INTERVAL: Concurrent administration with cholestyramine or colestipol may interfere with the absorption of some hydro-soluble vitamins such as folic acid.', NULL, 'Patients on prolonged cholestyramine or colestipol therapy should take folic acid supplements at least 1 hour before or 4 to 6 hours after receiving cholestyramine or colestipol.', NULL, 'Patients on prolonged cholestyramine or colestipol therapy should take folic acid supplements at least 1 hour before or 4 to 6 hours after receiving cholestyramine or colestipol.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338402, 'Folic acid', 'Valproic acid', 'Moderate', 'Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.', NULL, 'Caution is advised when folate therapy is coadministered with anticonvulsants.', NULL, 'Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338403, 'Anagrelide', 'Fondaparinux', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338404, 'Fondaparinux', 'Antithrombin Alfa', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338405, 'Fondaparinux', 'Antithrombin III human', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338406, 'Fondaparinux', 'Apixaban', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338407, 'Fondaparinux', 'Asparaginase Erwinia chrysanthemi', 'Moderate', 'Asparaginase therapy may lead to imbalances in coagulation factors predisposing the patient to bleeding or thrombosis. Theoretically, concurrent use of anticoagulants and asparaginase may increase the risk of bleeding. Hemorrhages grade 3 and above and CNS hemorrhages have been observed with asparaginase treatment.', NULL, 'Coagulation parameters should be monitored at baseline and periodically during concomitant treatment with asparaginase and anticoagulants such as heparin, dipyridamole, aspirin and nonsteroidal anti-inflammatory drugs.', NULL, 'Coagulation parameters should be monitored at baseline and periodically during concomitant treatment with asparaginase and anticoagulants such as heparin, dipyridamole, aspirin and nonsteroidal anti-inflammatory drugs. Patients should be advised to promptly report any signs and symptoms of bleeding.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338408, 'Fondaparinux', 'Asparaginase Escherichia coli', 'Moderate', 'Asparaginase therapy may lead to imbalances in coagulation factors predisposing the patient to bleeding or thrombosis. Theoretically, concurrent use of anticoagulants and asparaginase may increase the risk of bleeding. Hemorrhages grade 3 and above and CNS hemorrhages have been observed with asparaginase treatment.', NULL, 'Coagulation parameters should be monitored at baseline and periodically during concomitant treatment with asparaginase and anticoagulants such as heparin, dipyridamole, aspirin and nonsteroidal anti-inflammatory drugs.', NULL, 'Coagulation parameters should be monitored at baseline and periodically during concomitant treatment with asparaginase and anticoagulants such as heparin, dipyridamole, aspirin and nonsteroidal anti-inflammatory drugs. Patients should be advised to promptly report any signs and symptoms of bleeding.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338409, 'Fondaparinux', 'Acetylsalicylic acid', 'Major', 'In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs). The development of epidural and spinal hematoma can lead to long-term or permanent paralysis. Theoretically, NSAIDs may potentiate the risk of bleeding complications associated with the use of fondaparinux. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals.', NULL, 'Products containing NSAIDs, especially if given chronically or in high dosages, should preferably be discontinued prior to initiation of fondaparinux therapy.', NULL, 'Products containing NSAIDs, especially if given chronically or in high dosages, should preferably be discontinued prior to initiation of fondaparinux therapy. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits. Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338410, 'Fondaparinux', 'Avapritinib', 'Major', 'Coadministration of avapritinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', NULL, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution.', NULL, 'Concomitant use of avapritinib with other drugs that increase the risk of bleeding should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Patients should also seek immediate medical attention if they experience neurological signs and symptoms that may be associated with intracranial hemorrhage such as severe headache, vision problems, somnolence, or focal weakness. Brain imaging by magnetic resonance imaging (MRI) or computed tomography (CT) may be performed at the discretion of the physician based on severity and clinical presentation.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338411, 'Fondaparinux', 'Betrixaban', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338412, 'Fondaparinux', 'Bivalirudin', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338413, 'Fondaparinux', 'Bromfenac (ophthalmic)', 'Moderate', 'Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338414, 'Fondaparinux', 'Cabozantinib', 'Major', 'Coadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with cabozantinib is associated with severe, sometimes fatal hemorrhage including hemoptysis and gastrointestinal hemorrhage.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with cabozantinib.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with cabozantinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338415, 'Fondaparinux', 'Calaspargase pegol', 'Moderate', 'Asparaginase therapy may lead to imbalances in coagulation factors predisposing the patient to bleeding or thrombosis. Theoretically, concurrent use of anticoagulants and asparaginase may increase the risk of bleeding. Hemorrhages grade 3 and above and CNS hemorrhages have been observed with asparaginase treatment.', NULL, 'Coagulation parameters should be monitored at baseline and periodically during concomitant treatment with asparaginase and anticoagulants such as heparin, dipyridamole, aspirin and nonsteroidal anti-inflammatory drugs.', NULL, 'Coagulation parameters should be monitored at baseline and periodically during concomitant treatment with asparaginase and anticoagulants such as heparin, dipyridamole, aspirin and nonsteroidal anti-inflammatory drugs. Patients should be advised to promptly report any signs and symptoms of bleeding.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338416, 'Fondaparinux', 'Cangrelor', 'Major', 'Concomitant use of cangrelor with anticoagulants, thrombolytic agents, or other antiplatelet agents may theoretically increase the risk of bleeding.', NULL, 'Caution is recommended if cangrelor must be used in patients treated with other agents that alter hemostasis.', NULL, 'Caution is recommended if cangrelor must be used in patients treated with other agents that alter hemostasis. Patients should be monitored for potentially increased bleeding complications.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338417, 'Fondaparinux', 'Caplacizumab', 'Major', 'Concomitant use of caplacizumab with other agents that affect hemostasis such as anticoagulants, platelet aggregation inhibitors, thrombolytic agents, or drugs that cause thrombocytopenia may increase the risk of bleeding.', NULL, 'Caution is recommended if caplacizumab must be used with other agents that affect hemostasis.', NULL, 'Caution is recommended if caplacizumab must be used with other agents that affect hemostasis. Patients should be monitored for potential bleeding complications and therapy interrupted if clinically significant bleeding occurs. If needed, von Willebrand factor concentrate may be administered to rapidly correct hemostasis.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338418, 'Fondaparinux', 'Celecoxib', 'Moderate', 'Anticoagulants, antiplatelet agents, and thrombolytics may potentiate the risk of gastrointestinal bleeding complications associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors.', NULL, 'Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents.', NULL, 'Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents. Gastroprotective agents such as H2-receptor antagonists or proton pump inhibitors may be appropriate in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338419, 'Fondaparinux', 'Cilostazol', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338420, 'Fondaparinux', 'Citalopram', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338421, 'Fondaparinux', 'Clomipramine', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338422, 'Fondaparinux', 'Clopidogrel', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338423, 'Fondaparinux', 'Collagenase clostridium histolyticum', 'Moderate', 'The safety and efficacy of collagenase clostridium histolyticum in patients currently receiving, or within 7 days of receiving, anticoagulant medications other than low-dose aspirin (e.g., up to 150 mg/day) is unknown. Theoretically, the risk of bleeding complications may be increased.', NULL, 'Collagenase clostridium histolyticum should be used with caution in patients receiving or within 7 days of receiving anticoagulants (except for low-dose aspirin), platelet inhibitors, or thrombolytic agents.', NULL, 'Collagenase clostridium histolyticum should be used with caution in patients receiving or within 7 days of receiving anticoagulants (except for low-dose aspirin), platelet inhibitors, or thrombolytic agents.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338424, 'Fondaparinux', 'Dalteparin', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338425, 'Fondaparinux', 'Dasatinib', 'Major', 'Coadministration of dasatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with dasatinib is associated with severe thrombocytopenia.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with dasatinib.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with dasatinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. A complete blood count (CBC) with differential and platelet count should be obtained prior to and at least weekly for the first 2 months, then monthly thereafter or as clinically indicated. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338426, 'Fondaparinux', 'Deferasirox', 'Major', 'Coadministration with drugs that have known ulcerogenic or hemorrhagic potential may increase the risk of gastrointestinal bleeding associated with the use of deferasirox. Fatal gastrointestinal hemorrhages have been reported during deferasirox therapy, especially in elderly patients with advanced hematologic malignancies and/or low platelet counts.', NULL, 'Caution is advised if deferasirox is prescribed with drugs that have known ulcerogenic or hemorrhagic potential, including but not limited to NSAIDs, salicylates, corticosteroids, oral bisphosphonates, platelet inhibitors, anticoagulants, thrombolytic agents, or agents that commonly cause thrombocytopenia.', NULL, 'Caution is advised if deferasirox is prescribed with drugs that have known ulcerogenic or hemorrhagic potential, including but not limited to NSAIDs, salicylates, corticosteroids, oral bisphosphonates, platelet inhibitors, anticoagulants, thrombolytic agents, or agents that commonly cause thrombocytopenia. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, hematemesis, anorexia, and/or black, tarry stools.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338427, 'Fondaparinux', 'Defibrotide', 'Major', 'Coadministration of defibrotide with anticoagulants may increase the risk of bleeding. In vitro, defibrotide increased the activity of fibrinolytic enzymes; therefore, it may enhance the pharmacologic effects of antithrombotic agents.', NULL, 'Concomitant use of defibrotide with systemic anticoagulants (except for routine maintenance or reopening of central venous lines) is considered contraindicated.', NULL, 'Concomitant use of defibrotide with systemic anticoagulants (except for routine maintenance or reopening of central venous lines) is considered contraindicated. Anticoagulants should be discontinued prior to initiation of defibrotide. Preferably, defibrotide administration should be delayed until the effects of anticoagulant therapy have subsided. Some authorities recommend avoiding use of anticoagulants within 24 hours of defibrotide administration, or within 12 hours in the case of unfractionated heparin. Patients should be monitored for signs of bleeding during defibrotide therapy. If bleeding develops, defibrotide should be discontinued and treatment/supportive care provided until the bleeding stops.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338428, 'Fondaparinux', 'Deoxycholic acid', 'Moderate', 'Coadministration with agents that alter hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytics, or agents that commonly cause thrombocytopenia may increase the risk of submental hematoma or bruising in association with deoxycholic acid administration.', NULL, 'Deoxycholic acid should be used with caution in patients receiving drugs that may interfere with hemostasis.', NULL, 'Deoxycholic acid should be used with caution in patients receiving drugs that may interfere with hemostasis.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338429, 'Fondaparinux', 'Desirudin', 'Major', 'Drugs that can affect hemostasis such as dextrans, systemic glucocorticoids, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of desirudin. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during desirudin therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'During prophylaxis of venous thromboembolism, concomitant treatment with heparins or dextrans is not recommended.', NULL, 'During prophylaxis of venous thromboembolism, concomitant treatment with heparins or dextrans is not recommended. The effects of desirudin and unfractionated heparins on prolongation of activated partial thromboplastin time (aPTT) are additive. In general, any agent which may enhance the risk of hemorrhage should be discontinued prior to initiation of desirudin therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338430, 'Fondaparinux', 'Desvenlafaxine', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338431, 'Fondaparinux', 'Diclofenac (ophthalmic)', 'Moderate', 'Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338432, 'Fondaparinux', 'Diclofenac (topical)', 'Moderate', 'Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338433, 'Fondaparinux', 'Dipyridamole', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338434, 'Fondaparinux', 'Duloxetine', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338435, 'Fondaparinux', 'Edoxaban', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338436, 'Fosamprenavir', 'Alfuzosin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of alfuzosin, which is primarily metabolized by the isoenzyme. Severe hypotension and priapism may occur.', NULL, 'Concomitant use of alfuzosin with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated.', NULL, 'Concomitant use of alfuzosin with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated. Some authorities recommend avoiding concomitant use of alfuzosin during and for 2 weeks after treatment with itraconazole.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338437, 'Fosamprenavir', 'Aliskiren', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and P-glycoprotein may increase the plasma concentrations and pharmacologic effects of aliskiren, which is a substrate of both the isoenzyme and efflux transporter. According to the product labeling, plasma levels of aliskiren were increased approximately 80% by the potent CYP450 3A4 and moderate P-gp inhibitor ketoconazole at a dosage of 200 mg twice daily.', NULL, 'Pharmacologic response to aliskiren should be monitored more closely whenever a CYP450 3A4 and/or P-gp inhibitor is added to or withdrawn from therapy, and the aliskiren dosage adjusted if necessary.', NULL, 'Pharmacologic response to aliskiren should be monitored more closely whenever a CYP450 3A4 and/or P-gp inhibitor is added to or withdrawn from therapy, and the aliskiren dosage adjusted if necessary. Patients should be advised to notify their physician if they experience excessive adverse effects of aliskiren such as dizziness, lightheadedness, diarrhea, abdominal pain, and gastroesophageal reflux.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338438, 'Fosamprenavir', 'Almotriptan', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of almotriptan, which is partially metabolized by the isoenzyme.', NULL, 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, 'Caution is advised if almotriptan is used in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. The possibility of prolonged and/or increased pharmacologic effects of almotriptan, including serious adverse effects such as vasospastic reactions, should be considered during concomitant therapy. Patients should be advised to notify their physician if they experience nausea; pain or tightness in the chest, neck, or jaw; irregular heartbeat; abnormal breathing; seizures; tremor; and/or tingling or numbness.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338439, 'Fosamprenavir', 'Alogliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338440, 'Fosamprenavir', 'Alosetron', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of alosetron, which has been shown in vitro to be partially metabolized by the isoenzyme.', NULL, 'Because alosetron is associated with potentially serious and life-threatening, dose-related gastrointestinal adverse effects, caution is advised during concomitant use with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, 'Because alosetron is associated with potentially serious and life-threatening, dose-related gastrointestinal adverse effects, caution is advised during concomitant use with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Patients should be advised to immediately discontinue alosetron and notify their physician if they experience constipation or signs and symptoms of ischemic colitis such as rectal bleeding, bloody diarrhea, and new or worsening abdominal pain. Alosetron should not be resumed if ischemic colitis is diagnosed. Ischemic colitis and other serious complications such as obstruction, perforation, impaction, and toxic megacolon have resulted in hospitalization, blood transfusion, surgery, and death.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338441, 'Fosamprenavir', 'Alprazolam', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338442, 'Fosamprenavir', 'Ambrisentan', 'Minor', 'Based on in vitro data, coadministration with potent inhibitors of CYP450 3A4 and/or 2C19 may be expected to increase the plasma concentrations of ambrisentan, which is a substrate of these isoenzymes.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338443, 'Fosamprenavir', 'Amiodarone', 'Major', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may significantly increase the plasma concentrations of antiarrhythmic agents that are primarily metabolized by CYP450 3A4 such as amiodarone, bepridil, systemic lidocaine, and quinidine. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir. The interaction has not been specifically studied, but could conceivably lead to serious and/or life-threatening reactions including cardiac arrhythmias and other toxicities if levels are substantially increased. The use of amiodarone, bepridil, and quinidine has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.', NULL, 'Caution is advised if amprenavir or fosamprenavir must be used with antiarrhythmic agents that are substrates of CYP450 3A4.', NULL, 'Caution is advised if amprenavir or fosamprenavir must be used with antiarrhythmic agents that are substrates of CYP450 3A4. Pharmacologic response and plasma antiarrhythmic drug levels should be monitored more closely whenever amprenavir or fosamprenavir is added to or withdrawn from therapy, and the antiarrhythmic dosage adjusted as necessary. Concomitant use with amiodarone, bepridil, lidocaine, or quinidine is specifically contraindicated according to Canadian and European labeling.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338444, 'Amitriptyline', 'Fosamprenavir', 'Moderate', 'Product labeling for certain protease inhibitors (PIs) such as amprenavir and atazanavir states that serious and/or life-threatening drug interactions may occur with tricyclic antidepressants (TCAs), presumably due to PI inhibition of TCA metabolism via CYP450 3A4. High plasma levels of TCAs could conceivably lead to serious adverse reactions including QT interval prolongation and ventricular arrhythmias such as ventricular tachycardia and torsade de pointes. Moreover, many TCAs are thought to be substrates of multiple CYP450 isoenzymes, thus the effects of CYP450 3A4 inhibition alone are unknown. Some TCAs such as desipramine, doxepin, and nortriptyline are also thought to be primarily metabolized by CYP450 2D6, which is not known to be inhibited by most PIs (except ritonavir) to any significant extent.', NULL, 'Until further information is available, caution is advised if protease inhibitors must be used with certain TCAs.', NULL, 'Until further information is available, caution is advised if protease inhibitors must be used with certain TCAs. Pharmacologic response and plasma TCA levels should be monitored more closely whenever a PI is added to or withdrawn from therapy, and the TCA dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338445, 'Amlodipine', 'Fosamprenavir', 'Moderate', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme.', NULL, 'Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors.', NULL, 'Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors. Dosage reduction may be required for amlodipine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338446, 'Amobarbital', 'Fosamprenavir', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338447, 'Fosamprenavir', 'Apalutamide', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338448, 'Fosamprenavir', 'Apixaban', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of apixaban, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'No dosage adjustment for apixaban is required during concomitant therapy with lone inhibitors of CYP450 3A4 or P-gp, or moderate or weak dual inhibitors of both CYP450 3A4 and P-gp.', NULL, 'No dosage adjustment for apixaban is required during concomitant therapy with lone inhibitors of CYP450 3A4 or P-gp, or moderate or weak dual inhibitors of both CYP450 3A4 and P-gp. However, caution may be advisable. Closer monitoring of the pharmacologic effects of apixaban may be appropriate whenever a CYP450 3A4 or P-gp inhibitor is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338449, 'Fosamprenavir', 'Aprepitant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338450, 'Fosamprenavir', 'Aripiprazole', 'Moderate', 'Coadministration with ketoconazole or other potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of aripiprazole, which is partially metabolized by the isoenzyme.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever ketoconazole or other potent inhibitors of CYP450 3A4 (e.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever ketoconazole or other potent inhibitors of CYP450 3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, ketolide and certain macrolide antibiotics) are added to or withdrawn from therapy. The manufacturer recommends that aripiprazole dosage be reduced to one-half the normal dosage during concomitant administration with ketoconazole, and additional dosage adjustments be made based on clinical evaluation. Although clinical data are lacking, similar dosage adjustments may be appropriate during coadministration with other potent CYP450 3A4 inhibitors. Aripiprazole dosage should be increased accordingly if these agents are discontinued.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338451, 'Fosamprenavir', 'Armodafinil', 'Moderate', 'Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of protease inhibitors (PIs). The mechanism involves induction of intestinal CYP450 3A4-mediated first-pass metabolism by modafinil and armodafinil, with possible secondary induction of hepatic 3A4 metabolism. Significant intestinal metabolism appears to occur with indinavir and saquinavir but has not been studied with other PIs. Conversely, PIs may increase the plasma concentrations of modafinil via inhibition of hepatic CYP450 3A4 metabolism.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with decreased or subtherapeutic antiretroviral drug levels, caution is advised if modafinil or armodafinil must be used in patients treated with PIs, particularly if they are using only one PI in their antiretroviral regimen.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with decreased or subtherapeutic antiretroviral drug levels, caution is advised if modafinil or armodafinil must be used in patients treated with PIs, particularly if they are using only one PI in their antiretroviral regimen. Clinical monitoring for altered effects of both modafinil and the PI may be appropriate following addition or withdrawal of one or the other drug.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338452, 'Fosamprenavir', 'Atazanavir', 'Moderate', 'Coadministration with fosamprenavir may decrease the plasma concentrations of atazanavir, even in the presence of low-dose ritonavir as a pharmacokinetic booster. The mechanism has not been described. Atazanavir reportedly does not significantly affect the pharmacokinetics of amprenavir from fosamprenavir.', NULL, 'Appropriate dosages of atazanavir, fosamprenavir, and ritonavir with respect to safety and efficacy have not been established when used in combination.', NULL, 'Appropriate dosages of atazanavir, fosamprenavir, and ritonavir with respect to safety and efficacy have not been established when used in combination. Limited data suggest that an atazanavir dosage of 150 or 200 mg twice daily may be adequate in combination with fosamprenavir 700 mg and ritonavir 100 mg twice daily. Therapeutic drug monitoring is recommended if this regimen is used, and antiretroviral response should be monitored closely.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338453, 'Fosamprenavir', 'Atorvastatin', 'Major', 'Protease inhibitors (PIs), particularly ritonavir, may significantly increase the plasma concentrations of atorvastatin. The mechanism is PI inhibition of CYP450 3A4 metabolism.', NULL, 'The benefits of using atorvastatin in combination with protease inhibitors should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis.', NULL, 'The benefits of using atorvastatin in combination with protease inhibitors should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. A lower dosage of atorvastatin should be considered if concomitant use is required. Atorvastatin labeling recommends that the dosage not exceed 20 mg/day when used in combination with fosamprenavir or with dual protease inhibitor therapy consisting of ritonavir plus darunavir, saquinavir, or fosamprenavir. Use of atorvastatin with the fixed combination of atazanavir-cobicistat is not recommended. The dosage should not exceed 40 mg/day when used with nelfinavir. Fluvastatin, pitavastatin, and pravastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338454, 'Fosamprenavir', 'Avanafil', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.', NULL, 'The dosage of avanafil should not exceed 50 mg once every 24 hours when used in combination with moderate CYP450 3A4 inhibitors.', NULL, 'The dosage of avanafil should not exceed 50 mg once every 24 hours when used in combination with moderate CYP450 3A4 inhibitors.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338455, 'Fosamprenavir', 'Avapritinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', NULL, 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of avapritinib with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338456, 'Fosamprenavir', 'Avatrombopag', 'Moderate', 'Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in avatrombopag exposure is not expected to have a clinically important effect on platelet counts in patients with chronic liver disease scheduled to undergo a procedure due to the 5-day treatment duration.', NULL, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', NULL, 'No dose adjustment is recommended; however, it may be advisable to monitor platelet count for signs of decreased efficacy of avatrombopag.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338457, 'Fosamprenavir', 'Axitinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of axitinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of axitinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Should concomitant treatment with a potent inhibitor be required, the manufacturer recommends that axitinib dosage be reduced by approximately one-half, as this is predicted to adjust the axitinib systemic exposure (AUC) to the range observed without inhibitors; however, clinical data are lacking. Subsequent dosage adjustments can be made according to individual therapeutic response and tolerability.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338458, 'Fosamprenavir', 'Betamethasone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338459, 'Fosamprenavir', 'Bexarotene', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338460, 'Fosamprenavir', 'Bortezomib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.', NULL, 'Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.', NULL, 'Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338461, 'Fosamprenavir', 'Bosentan', 'Moderate', 'Coadministration of a protease inhibitor (PI) in combination with bosentan may increase the plasma concentration of bosentan and decrease that of the PI, unless ritonavir is included as a pharmacokinetic booster. Both PIs and bosentan are primarily metabolized by CYP450 3A4. Because PIs are also inhibitors of CYP450 3A4, they can inhibit the metabolic clearance of bosentan. Conversely, bosentan may induce the metabolism of PIs, although the effects are probably not significant in the presence of ritonavir, which is a potent CYP450 3A4 inhibitor.', NULL, 'Protease inhibitors should generally not be used in combination with bosentan unless ritonavir is also added as a pharmacokinetic booster.', NULL, 'Protease inhibitors should generally not be used in combination with bosentan unless ritonavir is also added as a pharmacokinetic booster. Dose adjustment of bosentan has been recommended. In patients who are starting bosentan and have been receiving PI therapy for at least 10 days, it has been recommended to start bosentan at 62.5 mg once daily or every other day based upon individual tolerability. When starting PI therapy in patients already on bosentan, it has been recommended to discontinue bosentan for at least 36 hours prior to initiation of PI therapy. After at least 10 days following the initiation of PI therapy, bosentan may be resumed at 62.5 mg once daily or every other day based upon individual tolerability. According to some authorities, use of the fixed combination atazanavir-cobicistat with bosentan is not recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338462, 'Fosamprenavir', 'Bosutinib', 'Major', 'Coadministration with potent and moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of bosutinib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of bosutinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of bosutinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of bosutinib during and for 2 weeks after treatment with itraconazole. If use of a potent or moderate CYP450 3A4 inhibitor is required, an interruption or a dosage reduction of bosutinib therapy should be considered.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338463, 'Fosamprenavir', 'Brentuximab vedotin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338464, 'Fosamprenavir', 'Brexpiprazole', 'Major', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these isoenzymes.', NULL, 'The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors.', NULL, 'The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors. The brexpiprazole dosage should be increased to the original level if these agents are discontinued. It is advisable to monitor patients for clinical response.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338465, 'Fosamprenavir', 'Brigatinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of brigatinib, which is partially metabolized by the isoenzyme.', NULL, 'Concomitant use of brigatinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of brigatinib with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the brigatinib once daily dose should be reduced by approximately 50% (i.e., from 180 mg to 90 mg, or from 90 mg to 60 mg). Patients should be closely monitored for increased adverse reactions such as nausea, vomiting, diarrhea, hypertension, bradycardia, hyperglycemia, visual disturbances, lymphopenia, anemia, and elevations in pancreatic enzymes and creatine phosphokinase. Following discontinuation of the CYP450 3A4 inhibitor, the brigatinib dose that was tolerated previously may be resumed.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338466, 'Fosamprenavir', 'Bromocriptine', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338467, 'Fosamprenavir', 'Budesonide', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic metabolism via intestinal and hepatic CYP450 3A4.', NULL, 'Concomitant use of budesonide with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of budesonide with potent CYP450 3A4 inhibitors should generally be avoided. Alternatives to budesonide should be considered whenever possible, particularly for long-term use. If an orally inhaled corticosteroid is necessary, a less potent, less lipophilic, and/or shorter-acting agent such as beclomethasone or flunisolide may be appropriate. If no alternatives exist and concomitant use is required, the dosing times between budesonide and the CYP450 3A4 inhibitor should be separated by as much as possible. In addition, the lowest effective dosage of budesonide should be prescribed, and further adjustments made as necessary according to therapeutic response and tolerance. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if budesonide is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression. Signs and symptoms of adrenal insufficiency include anorexia, hypoglycemia, nausea, vomiting, weight loss, muscle wasting, fatigue, weakness, dizziness, postural hypotension, depression, and adrenal crisis manifested as inability to respond to stress (e.g., illness, infection, surgery, trauma).', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338468, 'Fosamprenavir', 'Budesonide (nasal)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic metabolism via intestinal and hepatic CYP450 3A4. In pharmacokinetic studies, 6- to 8-fold increases in budesonide systemic exposure (AUC) have been observed during coadministration of the potent CYP450 3A4 inhibitor ketoconazole with different oral formulations of budesonide.', NULL, 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors.', NULL, 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors. If concomitant use cannot be avoided, the dosing times between budesonide and the CYP450 3A4 inhibitor should be separated by as much as possible. In addition, the lowest effective dosage of budesonide should be prescribed, and further adjustments made as necessary according to therapeutic response and tolerance.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338469, 'Fosamprenavir', 'Buprenorphine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of buprenorphine, which is partially metabolized (approximately 30%) by the isoenzyme.', NULL, 'Caution is advised if buprenorphine is prescribed with CYP450 3A4 inhibitors.', NULL, 'Caution is advised if buprenorphine is prescribed with CYP450 3A4 inhibitors. Induction with buprenorphine should begin at a reduced dosage, and dosage escalation should occur more slowly to allow for assessment of opiate effects and development of patient tolerance. In patients who are already stabilized on buprenorphine, pharmacologic response and vital signs should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the buprenorphine dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338470, 'Fosamprenavir', 'Buspirone', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338471, 'Fosamprenavir', 'Butorphanol', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of butorphanol according to the product labeling. Increased butorphanol concentrations could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Conversely, discontinuation of a CYP450 3A4 inhibitor could decrease butorphanol plasma concentrations, decrease opioid efficacy, and possibly even lead to a withdrawal syndrome in patients who had developed physical dependence to butorphanol.', NULL, 'Patients receiving butorphanol with potent or moderate CYP450 3A4 inhibitors should be carefully monitored, and dosage adjustments made accordingly as needed.', NULL, 'Patients receiving butorphanol with potent or moderate CYP450 3A4 inhibitors should be carefully monitored, and dosage adjustments made accordingly as needed. Patients and/or their caregivers should be advised to seek medical attention if potential signs and symptoms of toxicity occur, such as dizziness, confusion, fainting, extreme sedation, unresponsiveness, bradycardia, slow or difficult breathing, and shortness of breath. When discontinuing CYP450 3A4 inhibitors, monitor patients closely at frequent intervals and consider increasing the opioid dosage if needed to maintain adequate analgesia or if symptoms of opioid withdrawal occur.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338472, 'Fosamprenavir', 'Cabazitaxel', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cabazitaxel, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of cabazitaxel with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of cabazitaxel with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of cabazitaxel during and for 2 weeks after treatment with itraconazole.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338473, 'Fosamprenavir', 'Cabozantinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme. High plasma levels of cabozantinib may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Concomitant use of cabozantinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of cabozantinib with potent CYP450 3A4 inhibitors should generally be avoided. If concomitant use is required, the daily dosage of cabozantinib should be reduced by 40 mg (e.g., 140 mg to 100 mg daily; 100 mg to 60 mg daily). The original dosage may be resumed 2 to 3 days after discontinuation of the potent CYP450 3A4 inhibitor. However, some authorities recommend avoiding concomitant use of cabozantinib during and for 2 weeks after treatment with itraconazole. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Patients should also be advised regarding a potential increase in more common side effects of cabozantinib, such as diarrhea, fatigue, nausea, decreased appetite, palmar-plantar erythrodysesthesia syndrome (PPES), hypertension, vomiting, weight loss, and constipation.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338474, 'Fosamprenavir', 'Canagliflozin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338475, 'Fosamprenavir', 'Cannabidiol', 'Minor', 'Cannabidiol is a substrate for CYP450 3A4 and CYP450 2C19. Cannabidiol is metabolized in the liver and the gut (primarily in the liver) by CYP450 2C19 and CYP450 3A4 enzymes, and UGT1A7, UGT1A9, and UGT2B7 isoforms.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338476, 'Fosamprenavir', 'Capmatinib', 'Major', 'Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung disease, pneumonitis, and hepatotoxicity. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4, which is one of the primary enzymes responsible for the metabolic clearance of capmatinib.', NULL, 'Close monitoring is recommended whenever capmatinib is used with a strong CYP450 3A4 inhibitor.', NULL, 'Close monitoring is recommended whenever capmatinib is used with a strong CYP450 3A4 inhibitor. Clinical and laboratory monitoring should be considered whenever a strong CYP450 3A4 inhibitor is added to or withdrawn from therapy with capmatinib, and the dosage adjusted as necessary based on clinical response and toxicity. Patients should be monitored for the development of adverse effects.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338477, 'Fosamprenavir', 'Carbamazepine', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338478, 'Fosamprenavir', 'Cariprazine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cariprazine and its major active metabolite, didesmethyl cariprazine (DDCAR), both of which are primarily metabolized by the isoenzyme.', NULL, 'The dosage of cariprazine should be reduced in the presence of a potent CYP450 3A4 inhibitor.', NULL, 'The dosage of cariprazine should be reduced in the presence of a potent CYP450 3A4 inhibitor. When initiating a potent CYP450 3A4 inhibitor during stable treatment with cariprazine, the manufacturer recommends reducing the current dosage of cariprazine by one-half. For patients taking 4.5 mg daily, the dosage should be reduced to 1.5 mg or 3 mg daily. For patients taking 1.5 mg daily, the dosing interval should be adjusted to every other day. Conversely, if cariprazine therapy is initiated during treatment with a potent CYP450 3A4 inhibitor, the recommended starting dosage of cariprazine is 1.5 mg on day 1 and day 3, with no dose administered on day 2. From day 4 onward, the dosage should be 1.5 mg daily, then increased to a maximum dosage of 3 mg daily. Following withdrawal of the CYP450 3A4 inhibitor, the dosage of cariprazine may need to be increased.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338479, 'Fosamprenavir', 'Cenobamate', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338480, 'Fosamprenavir', 'Ceritinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death. Other, more common side effects such as diarrhea, nausea, vomiting, abdominal pain, hyperglycemia, and bradycardia may also increase.', NULL, 'Concomitant use of ceritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of ceritinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of ceritinib during and for 2 weeks after treatment with itraconazole. If coadministration is required, the manufacturer recommends a reduction of the ceritinib dosage by approximately one-third, rounded to the nearest 150 mg dosage strength. Patients should have periodic ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 500 msec on at least two separate ECGs will require suspension of ceritinib therapy and immediate action to correct any concomitant risk factors before resuming treatment with a 150 mg dosage reduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Following discontinuation of the potent CYP450 3A4 inhibitor, ceritinib therapy should be resumed at the dosage that was taken prior to initiating the CYP450 3A4 inhibitor.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338481, 'Fosamprenavir', 'Cevimeline', 'Moderate', 'Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of cevimeline, which is metabolized by these isoenzymes.', NULL, 'Dosage adjustments and clinical monitoring may be appropriate whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy.', NULL, 'Dosage adjustments and clinical monitoring may be appropriate whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience excessive adverse cholinergic effects of cevimeline such as nausea, vomiting, diarrhea, sweating, salivation, urinary frequency, visual disturbance, confusion, tremor, palpitations, or irregular heartbeat.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338482, 'Fosamprenavir', 'Chlordiazepoxide', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338483, 'Fosamprenavir', 'Chloroquine', 'Moderate', 'Coadministration with moderate or strong inhibitors of CYP450 2C8 or CYP450 3A4 may increase the plasma concentration of hydroxychloroquine and the risk of toxicities such as QT interval prolongation and ventricular arrhythmias.', NULL, 'Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a moderate or strong CYP450 3A4 or 2C8 inhibitor.', NULL, 'Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a moderate or strong CYP450 3A4 or 2C8 inhibitor. Clinical and laboratory monitoring should be considered whenever a moderate or strong CYP450 3A4 or 2C8 inhibitor is added to or withdrawn from therapy with hydroxychloroquine or chloroquine, and the dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338484, 'Fosamprenavir', 'Chlorpropamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338485, 'Fosamprenavir', 'Ciclesonide', 'Moderate', 'Coadministration of inhaled ciclesonide with potent inhibitors of CYP450 3A4 may increase systemic bioavailability of the pharmacologically active metabolite, des-ciclesonide, which is a substrate of the isoenzyme.', NULL, 'Caution is advised if ciclesonide is prescribed with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised if ciclesonide is prescribed with potent CYP450 3A4 inhibitors. Alternatively, a less potent, less lipophilic, and/or shorter-acting agent such as beclomethasone may be considered. Beclomethasone is also less dependent on CYP450 3A4 metabolism. Patients should be monitored for systemic glucocorticoid effects including symptoms of hypercorticism (e.g., acne, easy bruising, moon face, edema, hirsutism, buffalo hump, skin striae, irregular menstruations), adrenal suppression (which reduces patient''s ability to respond to stress situations), immunosuppression, osteoporosis, glucose intolerance, and exacerbation of diabetes mellitus.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338486, 'Fosamprenavir', 'Ciclesonide (nasal)', 'Moderate', 'Coadministration of inhaled ciclesonide with potent inhibitors of CYP450 3A4 may increase systemic bioavailability of the pharmacologically active metabolite, des-ciclesonide, which is a substrate of the isoenzyme.', NULL, 'Caution is advised if ciclesonide is prescribed with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised if ciclesonide is prescribed with potent CYP450 3A4 inhibitors. Alternatively, a less potent, less lipophilic, and/or shorter-acting agent such as beclomethasone may be considered. Beclomethasone is also less dependent on CYP450 3A4 metabolism. Patients should be monitored for systemic glucocorticoid effects including symptoms of hypercorticism (e.g., acne, easy bruising, moon face, edema, hirsutism, buffalo hump, skin striae, irregular menstruations), adrenal suppression (which reduces patient''s ability to respond to stress situations), immunosuppression, osteoporosis, glucose intolerance, and exacerbation of diabetes mellitus.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338487, 'Fosamprenavir', 'Cilostazol', 'Major', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active metabolites, which are substrates of these isoenzymes. The possibility of prolonged and/or increased pharmacologic effects of cilostazol should be considered.', NULL, 'A 50% dosage reduction of cilostazol (i.', NULL, 'A 50% dosage reduction of cilostazol (i.e., 50 mg twice a day) should be considered when used with potent or moderate CYP450 3A4 and/or 2C19 inhibitors. Close clinical and laboratory monitoring is advised whenever the inhibitor is added to or withdrawn from therapy, and the cilostazol dosage adjusted as necessary. Patients should be advised to contact their physician if they experience adverse effects of cilostazol such as dizziness, nausea, diarrhea, bleeding, or irregular heartbeat.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338488, 'Fosamprenavir', 'Cimetidine', 'Moderate', 'Coadministration with H2-receptor antagonists or proton pump inhibitors may decrease the oral bioavailability of amprenavir from its prodrug, fosamprenavir. It is possible that fosamprenavir solubility decreases with increasing pH, thus inhibition of gastric acid secretion may interfere with dissolution of the drug. Subtherapeutic antiretroviral drug levels may lead to reduced viral susceptibility and development of resistance.', NULL, 'Caution is advised if fosamprenavir is prescribed with H2-receptor antagonists or proton pump inhibitors.', NULL, 'Caution is advised if fosamprenavir is prescribed with H2-receptor antagonists or proton pump inhibitors. Antiretroviral response should be monitored closely during coadministration.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338489, 'Fosamprenavir', 'Cinacalcet', 'Moderate', 'Coadministration with ketoconazole or other potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cinacalcet, which is partially metabolized by the isoenzyme.', NULL, 'Pharmacologic response to cinacalcet (i.', NULL, 'Pharmacologic response to cinacalcet (i.e., parathyroid hormone and serum calcium levels) should be monitored more closely whenever potent inhibitors of CYP450 3A4 are added to or withdrawn from therapy, and the cinacalcet dosage adjusted accordingly.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338490, 'Fosamprenavir', 'Citalopram', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338491, 'Fosamprenavir', 'Clarithromycin', 'Minor', 'Drugs that act as both substrate and inhibitor of the CYP450 3A4 isoenzyme may alter the plasma concentration of amprenavir. Amprenavir may increase blood levels of the CYP450 3A4 inhibitor. The extent of the alterations in serum drug levels is unknown and the clinical significance is uncertain. When concomitant therapy is required, the patient should be monitored for adverse effects of both drugs and dose adjustments made when indicated.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338492, 'Fosamprenavir', 'Clindamycin', 'Moderate', 'Coadministration with strong CYP450 3A4 inhibitors may increase plasma concentrations and the risk of adverse effects of clindamycin, which is metabolized predominantly by the isoenzyme.', NULL, 'Caution is advised if clindamycin is used concomitantly with strong CYP450 3A4 inhibitors.', NULL, 'Caution is advised if clindamycin is used concomitantly with strong CYP450 3A4 inhibitors. The possibility of adverse reactions to clindamycin should be considered during coadministration with strong CYP450 3A4 inhibitors. Dosage adjustments as well as clinical and laboratory monitoring of clindamycin should be considered whenever a strong CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338493, 'Fosamprenavir', 'Clobazam', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338494, 'Fosamprenavir', 'Clonazepam', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338495, 'Fosamprenavir', 'Clorazepic acid', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338496, 'Fosamprenavir', 'Cobicistat', 'Moderate', 'Cobicistat may increase the plasma concentrations of antiretroviral agents. The plasma concentrations of cobicistat may also be increased or reduced in the presence of antiretroviral agents. The proposed mechanism is cobicistat inhibition of the CYP450 3A4 isoenzyme, of which antiretroviral agents may be substrates, and the inhibition or induction of CYP450 3A4 by concomitant antiretroviral medications.', NULL, 'Cobicistat is not intended for use with more than one antiretroviral medication that requires pharmacokinetic enhancement, such as two protease inhibitors or elvitegravir in combination with a protease inhibitor.', NULL, 'Cobicistat is not intended for use with more than one antiretroviral medication that requires pharmacokinetic enhancement, such as two protease inhibitors or elvitegravir in combination with a protease inhibitor. In addition, cobicistat should not be used concomitantly with ritonavir due to their similar effects on CYP450 3A4. According to some authorities, use of the antiretroviral combinations of atazanavir-cobicistat or darunavir-cobicistat concomitantly with the CYP450 3A4 inducers efavirenz, etravirine, or nevirapine is also not recommended.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338497, 'Fosamprenavir', 'Cobimetinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cobimetinib, which is primarily metabolized by the isoenzyme. The risk and/or severity of adverse effects such as diarrhea, nausea, vomiting, stomatitis, hemorrhage, cardiomyopathy, rash, photosensitivity, retinopathy, retinal vein occlusion, liver enzyme abnormalities, and rhabdomyolysis may be increased.', NULL, 'Concomitant use of cobimetinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of cobimetinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of cobimetinib during and for 2 weeks after treatment with itraconazole.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338498, 'Fosamprenavir', 'Cocaine (topical)', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338499, 'Fosamprenavir', 'Colchicine', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may significantly increase the serum concentrations of colchicine, which is primarily metabolized by the isoenzyme. Clinical toxicity including myopathy, neuropathy, multiorgan failure, and pancytopenia may occur.', NULL, 'Caution is advised if colchicine is prescribed in combination with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if colchicine is prescribed in combination with moderate CYP450 3A4 inhibitors. In patients with normal renal and hepatic function, the dosage of colchicine should be reduced when used with moderate CYP450 3A4 inhibitors or within 14 days of using them. For the treatment of acute gout flares, the adjusted dosage recommended is 1.2 mg for one dose. Administration should not be repeated for at least three days. For the prophylaxis of gout flares, the adjusted dosage should be 0.3 mg twice a day (or 0.6 mg once a day) if the original regimen was 0.6 mg twice a day, and 0.3 mg once a day if the original regimen was 0.6 once a day. For the treatment of familial Mediterranean fever, the maximum dosage of colchicine is 1.2 mg/day (may be given as 0.6 mg twice a day) when used in the presence of moderate CYP450 3A4 inhibitors. Other significant inhibitors of CYP450 3A4 include amiodarone, dronedarone, imatinib, posaconazole, and quinupristin-dalfopristin, although the extent to which they may interact with colchicine is unknown. A similar dosage adjustment may be required. Patients should be advised to contact their physician if they experience symptoms of toxicity such as abdominal pain, nausea, vomiting, diarrhea, fatigue, myalgia, asthenia, hyporeflexia, paresthesia, and numbness.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338500, 'Fosamprenavir', 'Conivaptan', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of vasopressin receptor antagonists conivaptan and tolvaptan, both of which are almost exclusively metabolized by the isoenzyme.', NULL, 'Concomitant use of conivaptan or tolvaptan with potent CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Concomitant use of conivaptan or tolvaptan with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities recommend avoiding concomitant use of conivaptan or tolvaptan during and for 2 weeks after treatment with itraconazole.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338501, 'Fosamprenavir', 'Crizotinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of crizotinib, which is primarily metabolized by the isoenzyme. Because crizotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.', NULL, 'Concomitant use of crizotinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of crizotinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of crizotinib during and for 2 weeks after treatment with itraconazole.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338502, 'Fosamprenavir', 'Cyclophosphamide', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338503, 'Fosamprenavir', 'Cyclosporine', 'Major', 'Coadministration with protease inhibitors (PIs), especially ritonavir, may significantly increase the blood concentrations of cyclosporine. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased. The mechanism involves PI inhibition of CYP450 3A4, the isoenzyme responsible for the intestinal and hepatic metabolism of cyclosporine. Enhanced cyclosporine oral bioavailability due to PI inhibition of intestinal P-glycoprotein efflux transporter may also contribute.', NULL, 'Caution is advised if cyclosporine is used in combination with protease inhibitors.', NULL, 'Caution is advised if cyclosporine is used in combination with protease inhibitors. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of PI therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Patients treated with saquinavir should also be monitored for potential PI toxicity and the dosage adjusted accordingly.', 'Metabolism, Absorption', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338504, 'Fosamprenavir', 'Dabrafenib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 and/or 2C8 may increase the plasma concentrations of dabrafenib and its active metabolites. Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, including many of the known inhibitors of the isoenzyme such as conivaptan, delavirdine, nefazodone, telithromycin, and most azole antifungal agents, macrolide antibiotics, and protease inhibitors.', NULL, 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible.', NULL, 'The use of dabrafenib with potent CYP450 2C8 inhibitors such as gemfibrozil or potent CYP450 3A4 inhibitors such as ceritinib, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents should generally be avoided if possible. Some authorities recommend avoiding concomitant use of dabrafenib during and for 2 weeks after treatment with itraconazole. Otherwise, patients should be closely monitored for development of adverse effects such as febrile reactions (high fever or fever accompanied by rigors, hypotension, dehydration, or renal failure), hyperglycemia, uveitis, and cutaneous malignancies (e.g., squamous cell carcinoma, keratoacanthoma, melanoma).', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338505, 'Fosamprenavir', 'Daclatasvir', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.', NULL, 'Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338506, 'Fosamprenavir', 'Dapagliflozin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338507, 'Fosamprenavir', 'Darifenacin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by the isoenzyme. Darifenacin is also metabolized by CYP450 2D6, but 3A4 is the major pathway of metabolism in so-called poor metabolizers of 2D6.', NULL, 'The dosage of darifenacin should not exceed 7.', NULL, 'The dosage of darifenacin should not exceed 7.5 mg/day when used with potent CYP450 3A4 inhibitors. Some authorities recommend avoiding concomitant use of darifenacin during and for 2 weeks after treatment with itraconazole.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338508, 'Fosamprenavir', 'Darolutamide', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338509, 'Fosamprenavir', 'Dasatinib', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of dasatinib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of dasatinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of dasatinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of dasatinib during and for 2 weeks after treatment with itraconazole. Close monitoring for toxicity (e.g., myelosuppression, bleeding complications, fluid retention, excessive slowing of heart rate or other conduction disturbances) and a reduction of dasatinib dosage to a range of 20 to 40 mg daily should be considered if there are no alternatives and concomitant use with these agents is necessary.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338510, 'Fosamprenavir', 'Deferasirox', 'Moderate', 'Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism may involve induction of CYP450 3A4 activity by deferasirox, although in vitro, the drug has been shown to inhibit CYP450 3A4.', NULL, 'Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever deferasirox is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338511, 'Fosamprenavir', 'Deflazacort', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of 21-desdeflazacort, the active metabolite of deflazacort that is formed by esterases after oral administration and further metabolized by CYP450 3A4 to several inactive metabolites.', NULL, 'The manufacturer suggests using one-third of the recommended dosage of deflazacort when coadministered with potent or moderate CYP450 3A4 inhibitors.', NULL, 'The manufacturer suggests using one-third of the recommended dosage of deflazacort when coadministered with potent or moderate CYP450 3A4 inhibitors. Some authorities recommend avoiding concomitant use of deflazacort and CYP450 3A inhibitors unless the benefit outweighs the risk, in which case patients should be monitored for systemic corticosteroid side effects.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338512, 'Fosamprenavir', 'Delavirdine', 'Major', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may significantly decrease the plasma concentrations of delavirdine. The exact mechanism of interaction has not been established. Conversely, delavirdine may increase the plasma concentrations of amprenavir by inhibiting CYP450 3A4 metabolism.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of delavirdine with amprenavir or fosamprenavir is considered contraindicated.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, concomitant use of delavirdine with amprenavir or fosamprenavir is considered contraindicated.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338513, 'Fosamprenavir', 'Dexamethasone (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338514, 'Fosamprenavir', 'Dexlansoprazole', 'Moderate', 'Coadministration with H2-receptor antagonists or proton pump inhibitors may decrease the oral bioavailability of amprenavir from its prodrug, fosamprenavir. It is possible that fosamprenavir solubility decreases with increasing pH, thus inhibition of gastric acid secretion may interfere with dissolution of the drug. Subtherapeutic antiretroviral drug levels may lead to reduced viral susceptibility and development of resistance.', NULL, 'Caution is advised if fosamprenavir is prescribed with H2-receptor antagonists or proton pump inhibitors.', NULL, 'Caution is advised if fosamprenavir is prescribed with H2-receptor antagonists or proton pump inhibitors. Antiretroviral response should be monitored closely during coadministration.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338515, 'Fosamprenavir', 'Diazepam', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338516, 'Fosamprenavir', 'Dihydroergotamine', 'Major', 'Coadministration with protease inhibitors (PIs), particularly ritonavir, may significantly increase the plasma concentrations of ergot derivatives. The mechanism is PI inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ergotamine and related drugs.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with protease inhibitors is considered contraindicated.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with protease inhibitors is considered contraindicated.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338517, 'Fosamprenavir', 'Disopyramide', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if amprenavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever amprenavir is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338518, 'Fosamprenavir', 'Docetaxel', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 or dual CYP450 3A4 and P-glycoprotein (P-gp) inhibitors may significantly increase the plasma concentrations of docetaxel, which is a substrate of both CYP450 3A4 and P-gp.', NULL, 'Concomitant use of docetaxel with CYP450 3A4 inhibitors, particularly potent inhibitors or dual CYP450 3A4 and P-gp inhibitors such as itraconazole, ketoconazole, posaconazole, conivaptan, ceritinib, idelalisib, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics, should generally be avoided.', NULL, 'Concomitant use of docetaxel with CYP450 3A4 inhibitors, particularly potent inhibitors or dual CYP450 3A4 and P-gp inhibitors such as itraconazole, ketoconazole, posaconazole, conivaptan, ceritinib, idelalisib, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics, should generally be avoided. Some authorities recommend avoiding concomitant use of docetaxel during and for 2 weeks after treatment with itraconazole. If concomitant use is required, a reduced dosage of docetaxel should be considered. Based on extrapolation from the pharmacokinetic study in 7 cancer patients, a 50% reduction in the docetaxel dose may be reasonable. Patients should be closely monitored for the development of docetaxel toxicity such as myelosuppression, stomatitis, neurotoxicity (e.g., paraesthesia, dysesthesia, pain), myalgia, asthenia, fluid retention, nausea, vomiting, and diarrhea.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338519, 'Fosamprenavir', 'Dofetilide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of dofetilide, which is partially metabolized by the isoenzyme. The use of dofetilide has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.', NULL, 'Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage of dofetilide adjusted accordingly as necessary.', NULL, 'Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage of dofetilide adjusted accordingly as necessary. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338520, 'Fosamprenavir', 'Donepezil', 'Minor', 'Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of donepezil, which is primarily metabolized by these isoenzymes.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338521, 'Fosamprenavir', 'Doravirine', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338522, 'Fosamprenavir', 'Doxazosin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations and effects of doxazosin. In vitro studies suggest that the primary pathway for elimination of doxazosin is via CYP450 3A4.', NULL, 'Caution is advised if doxazosin is used concomitantly with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised if doxazosin is used concomitantly with potent CYP450 3A4 inhibitors. Blood pressure and pharmacologic response to doxazosin should be monitored closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the doxazosin dosage adjusted if necessary. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, orthostasis, syncope, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medication affects them.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338523, 'Fosamprenavir', 'Dronedarone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of dronedarone, which is primarily metabolized by the isoenzyme. Because dronedarone is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.', NULL, 'The use of dronedarone in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, cyclosporine, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated.', NULL, 'The use of dronedarone in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, cyclosporine, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated. Patients currently receiving these agents should stop taking them before starting treatment with dronedarone. Some authorities consider concomitant administration of dronedarone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338524, 'Fosamprenavir', 'Droperidol', 'Moderate', 'Coadministration with drugs that are potent inhibitors of CYP450 3A4 and/or 1A2 may increase the plasma concentrations of droperidol, which is predicted to be metabolized by these isoenzymes. While clinical data are lacking, the possibility of prolonged pharmacological action and adverse effects such as central nervous system depression, extrapyramidal reactions, tardive dyskinesia, hypotension, and prolongation of the QT interval should be considered.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of droperidol should be considered during coadministration of potent inhibitors of CYP450 3A4 and/or 1A2.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of droperidol should be considered during coadministration of potent inhibitors of CYP450 3A4 and/or 1A2. Some manufacturers advise that to minimize the risk of ventricular arrhythmia, an ECG should be performed in all patients prior to initiating therapy with droperidol and periodically thereafter. Therapeutic response to droperidol should be monitored more closely following initiation, discontinuation, or dosing change of the concomitant inhibitor, and the droperidol dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338525, 'Fosamprenavir', 'Drospirenone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by the isoenzyme. High exposure to drospirenone may potentiate the risk hyperkalemia. Drospirenone has antimineralocorticoid activity and can induce hyperkalemia in susceptible patients.', NULL, 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.', NULL, 'Caution and close clinical monitoring are recommended, especially in patients requiring long-term use and those at increased risk for hyperkalemia (e.g., patients with renal impairment, those receiving potassium-sparing medications). Because of the risk for hyperkalemia, concomitant use with certain CYP450 3A4 inhibitors such as boceprevir or atazanavir boosted with cobicistat, is considered contraindicated by the manufacturers. Consider checking potassium levels during the first treatment cycle of concomitant drospirenone use and then periodically as indicated.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338526, 'Fosamprenavir', 'Dulaglutide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338527, 'Fosamprenavir', 'Dutasteride', 'Moderate', 'Based on in vitro data, coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of dutasteride, which is metabolized by the isoenzyme.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of dutasteride should be considered during concomitant therapy with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of dutasteride should be considered during concomitant therapy with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338528, 'Fosamprenavir', 'Duvelisib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of duvelisib, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised when duvelisib is used with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when duvelisib is used with CYP450 3A4 inhibitors. Patients should be monitored for the development of toxicities such as diarrhea, colitis, neutropenia, thrombocytopenia, pneumonitis, infections, cutaneous reactions and hepatotoxicity, and the dosing adjusted or discontinued in accordance with the duvelisib product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338529, 'Fosamprenavir', 'Efavirenz', 'Moderate', 'Coadministration with efavirenz may decrease the plasma concentrations of amprenavir. The mechanism is efavirenz induction of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of amprenavir.', NULL, 'The dosage of amprenavir or its prodrug, fosamprenavir, should probably be increased when coadministered with efavirenz in the absence of ritonavir as a pharmacokinetic booster, although appropriate dosages with respect to safety and efficacy have not been established.', NULL, 'The dosage of amprenavir or its prodrug, fosamprenavir, should probably be increased when coadministered with efavirenz in the absence of ritonavir as a pharmacokinetic booster, although appropriate dosages with respect to safety and efficacy have not been established. Fosamprenavir labeling recommends an additional 100 mg/day (300 mg total) of ritonavir when efavirenz is administered with the fosamprenavir-ritonavir once-daily regimen based on pharmacokinetic studies. No change in the ritonavir dose is required when efavirenz is administered with the fosamprenavir-ritonavir twice-daily regimen.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338530, 'Fosamprenavir', 'Elagolix', 'Moderate', 'Coadministration with drugs that are inducers of CYP450 3A4 may decrease the plasma concentrations of protease inhibitors (PIs), which are primarily metabolized by the isoenzyme.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, protease inhibitors should be used cautiously with agents that induce CYP450 3A4, particularly if only one PI is used in the antiretroviral regimen. Coadministration of atazanavir without ritonavir and carbamazepine, phenobarbital, or phenytoin is not recommended. Antiretroviral response should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the antiretroviral regimen adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338531, 'Fosamprenavir', 'Eletriptan', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eletriptan, which is primarily metabolized by the isoenzyme. Clinically, this interaction may result in increased risk of vasospastic reactions associated with the use of 5-HT1 receptor agonists, such as coronary artery vasospasm, peripheral vascular ischemia, and colonic ischemia.', NULL, 'Eletriptan should not be used within at least 72 hours of treatment with potent CYP450 3A4 inhibitors.', NULL, 'Eletriptan should not be used within at least 72 hours of treatment with potent CYP450 3A4 inhibitors. Alternatively, other 5-HT1 receptor agonists that are not metabolized by CYP450 3A4 may be considered, such as frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338532, 'Fosamprenavir', 'Eliglustat', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.', NULL, 'The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs).', NULL, 'The use of eliglustat with a potent CYP450 3A4 inhibitor is considered contraindicated in CYP450 2D6 poor metabolizers (PMs) and intermediate metabolizers (IMs). The contraindication is extended to extensive metabolizers (EMs) when a moderate or potent CYP450 2D6 inhibitor is given concomitantly with a moderate or potent CYP450 3A4 inhibitor. In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a potent CYP450 3A4 inhibitor. Potent CYP450 3A4 inhibitors include itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, ceritinib, idelalisib, mibefradil, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, dronedarone, duloxetine, flecainide, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propafenone, propoxyphene, quinidine, ranolazine, sertraline, and terbinafine. Some drugs such as cobicistat, delavirdine, mibefradil, and ritonavir are dual CYP450 3A4 and 2D6 inhibitors, and they should not be used with eliglustat in any patient regardless of their CYP450 2D6 metabolizer status.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338533, 'Fosamprenavir', 'Eluxadoline', 'Moderate', 'It is not known whether, and to what extent, eluxadoline may be metabolized by CYP450 isoenzymes and may interact with inhibitors of CYP450 isoenzymes.', NULL, 'As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes.', NULL, 'As a precautionary measure due to incomplete information on the metabolism of eluxadoline, the manufacturer recommends caution during coadministration with potent inhibitors of various CYP450 isoenzymes. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis,', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338534, 'Fosamprenavir', 'Empagliflozin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338535, 'Fosamprenavir', 'Encorafenib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. Increased exposure to encorafenib may increase the risk of serious and life-threatening adverse effects such as hemorrhage, uveitis, QT prolongation, hepatotoxicity, dermatologic reactions, and new malignancies.', NULL, 'Concomitant use of encorafenib with moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of encorafenib with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the encorafenib dose to one-half of the dose used prior to addition of the moderate CYP450 3A4 inhibitor. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, the encorafenib dose that was taken prior to initiating the inhibitor may be resumed.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338536, 'Fosamprenavir', 'Enfortumab vedotin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of enfortumab vedotin. Enfortumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when enfortumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised when enfortumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors. Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, hyperglycemia, dermatologic reactions (maculopapular rash, pruritus, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, palmar-plantar erythrodysesthesia), and ocular disorders (dry eyes, keratitis, blurred vision, limbal stem cell deficiency), and the dosing of enfortumab vedotin adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338537, 'Fosamprenavir', 'Loperamide', 'Major', 'Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors) may increase the plasma concentrations and adverse effects of loperamide.', NULL, 'Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism.', NULL, 'Caution is recommended if loperamide is used with drugs that enhance its gastrointestinal absorption or inhibit its metabolism. Particular caution is advised when drugs that inhibit CYP450 3A4 (e.g., azole antifungal agents, clarithromycin, cobicistat, conivaptan, delavirdine, erythromycin, idelalisib, nefazodone, protease inhibitors, telithromycin) and CYP450 2C8 (e.g., gemfibrozil, clopidogrel) are used together with loperamide, or when one or more of these drugs are combined with inhibitors of P-glycoprotein transport (e.g., amiodarone, cyclosporine, diltiazem, dronedarone, quinidine, verapamil), since they may act synergistically to increase loperamide concentrations. Patients should be counseled to not exceed the recommended dosage and frequency or duration of use of loperamide, and to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If loperamide-induced cardiotoxicity is suspected, promptly discontinue loperamide and initiate therapy to manage and prevent cardiac arrhythmias and adverse outcomes. Electrical pacing or cardioversion may be necessary if torsade de pointes persists despite pharmacotherapy.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338538, 'Fosamprenavir', 'Methadone', 'Moderate', 'Methadone may decrease the plasma concentrations of amprenavir in the absence of low-dose ritonavir as a pharmacokinetic booster. Coadministration with fosamprenavir alone or in combination with low-dose ritonavir may decrease the plasma concentrations of methadone. The exact mechanism of interaction has not been described.', NULL, 'Based on available pharmacokinetic data, the interaction between methadone and fosamprenavir/ritonavir is not expected to be clinically significant.', NULL, 'Based on available pharmacokinetic data, the interaction between methadone and fosamprenavir/ritonavir is not expected to be clinically significant. However, as a precaution, patients should be monitored for opiate withdrawal symptoms if prescribed fosamprenavir/ritonavir while receiving methadone treatment. Patients should be advised to notify their caregiver if they experience symptoms of methadone withdrawal such as restlessness, insomnia, sweating, lacrimation, or rhinorrhea. Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, fosamprenavir should preferably not be used with methadone in the absence of ritonavir as a pharmacokinetic booster.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338539, 'Fosaprepitant', 'Alfuzosin', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of alfuzosin, which is primarily metabolized by the isoenzyme. Hypotension, syncope, QT prolongation, and priapism may occur.', NULL, 'Caution is advised if alfuzosin is prescribed in combination with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if alfuzosin is prescribed in combination with moderate CYP450 3A4 inhibitors. Pharmacologic response to alfuzosin should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the alfuzosin dosage adjusted as necessary. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, orthostasis, syncope, or tachycardia. Taking alfuzosin at bedtime may minimize the occurrence of orthostatic effects. Patients should also avoid driving or operating hazardous machinery until they know how the medication affects them.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338540, 'Fosaprepitant', 'Aliskiren', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and P-glycoprotein may increase the plasma concentrations and pharmacologic effects of aliskiren, which is a substrate of both the isoenzyme and efflux transporter. According to the product labeling, plasma levels of aliskiren were increased approximately 80% by the potent CYP450 3A4 and moderate P-gp inhibitor ketoconazole at a dosage of 200 mg twice daily.', NULL, 'Pharmacologic response to aliskiren should be monitored more closely whenever a CYP450 3A4 and/or P-gp inhibitor is added to or withdrawn from therapy, and the aliskiren dosage adjusted if necessary.', NULL, 'Pharmacologic response to aliskiren should be monitored more closely whenever a CYP450 3A4 and/or P-gp inhibitor is added to or withdrawn from therapy, and the aliskiren dosage adjusted if necessary. Patients should be advised to notify their physician if they experience excessive adverse effects of aliskiren such as dizziness, lightheadedness, diarrhea, abdominal pain, and gastroesophageal reflux.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338541, 'Fosaprepitant', 'Almotriptan', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338542, 'Fosaprepitant', 'Alosetron', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 2C9. The mechanism is accelerated clearance due to induction of CYP450 2C9 activity by aprepitant.', NULL, 'Caution is advised if aprepitant or fosaprepitant must be used concomitantly with medications that undergo metabolism by CYP450 2C9, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if aprepitant or fosaprepitant must be used concomitantly with medications that undergo metabolism by CYP450 2C9, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338543, 'Fosaprepitant', 'Alprazolam', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of benzodiazepines that are metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4. The potential for increased pharmacologic effects of the benzodiazepine, including central nervous system and respiratory depression, should be considered. The interaction is not expected to occur with lorazepam, oxazepam or temazepam, which are primarily metabolized via glucuronidation. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338544, 'Fosaprepitant', 'Amiodarone', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338545, 'Amlodipine', 'Fosaprepitant', 'Moderate', 'Coadministration with CYP450 3A4 inhibitors may increase the plasma concentrations of amlodipine, which is a substrate of the isoenzyme.', NULL, 'Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors.', NULL, 'Close monitoring of clinical response and tolerance is recommended if amlodipine is prescribed with potent or moderate CYP450 3A4 inhibitors. Dosage reduction may be required for amlodipine. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338546, 'Amobarbital', 'Fosaprepitant', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St.', NULL, 'The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St. John''s wort. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338547, 'Fosaprepitant', 'Apixaban', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of apixaban, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'No dosage adjustment for apixaban is required during concomitant therapy with lone inhibitors of CYP450 3A4 or P-gp, or moderate or weak dual inhibitors of both CYP450 3A4 and P-gp.', NULL, 'No dosage adjustment for apixaban is required during concomitant therapy with lone inhibitors of CYP450 3A4 or P-gp, or moderate or weak dual inhibitors of both CYP450 3A4 and P-gp. However, caution may be advisable. Closer monitoring of the pharmacologic effects of apixaban may be appropriate whenever a CYP450 3A4 or P-gp inhibitor is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338548, 'Fosaprepitant', 'Aripiprazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of aripiprazole, which is primarily metabolized by these isoenzymes.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 and/or 2D6 inhibitor is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.', NULL, 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 and/or 2D6 inhibitor is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary. The manufacturer recommends that aripiprazole dosage be reduced to one-half the normal dosage during concomitant administration with ketoconazole or quinidine, and additional dosage adjustments be made based on clinical evaluation.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338549, 'Fosaprepitant', 'Armodafinil', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are both partially metabolized by the isoenzyme. Conversely, the plasma levels of some of these inhibitors may decrease, since many of them are also substrates of CYP450 3A4, and modafinil and armodafinil have been found to be modest inducers of CYP450 3A4. The clinical significance of this potential interaction is unknown. Clinical monitoring for altered effects of modafinil and armodafinil as well as the CYP450 3A4 inhibitor may be appropriate following addition or withdrawal of one or the other drug.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338550, 'Fosaprepitant', 'Atazanavir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338551, 'Fosaprepitant', 'Atorvastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', NULL, 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', NULL, 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338552, 'Fosaprepitant', 'Avanafil', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme.', NULL, 'The dosage of avanafil should not exceed 50 mg once every 24 hours when used in combination with moderate CYP450 3A4 inhibitors.', NULL, 'The dosage of avanafil should not exceed 50 mg once every 24 hours when used in combination with moderate CYP450 3A4 inhibitors.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338553, 'Fosaprepitant', 'Avapritinib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. Increased exposure to avapritinib may increase the risk and/or severity of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils, and platelets.', NULL, 'Concomitant use of avapritinib with moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of avapritinib with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the starting dosage of avapritinib from 300 mg orally once daily to 100 mg orally once daily.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338554, 'Fosaprepitant', 'Axitinib', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338555, 'Fosaprepitant', 'Benzphetamine', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338556, 'Fosaprepitant', 'Betamethasone', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338557, 'Fosaprepitant', 'Bexarotene', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may theoretically increase the plasma concentrations of bexarotene. In vitro studies suggest that bexarotene is metabolized by CYP450 3A4. However, concomitant administration with multiple doses of ketoconazole, a potent CYP450 3A4 inhibitor, did not alter bexarotene plasma concentrations, which would imply that bexarotene elimination is not substantially dependent on CYP450 3A4 metabolism in vivo. Conversely, bexarotene appears to be an inducer of CYP450 3A4 and may reduce the plasma concentrations of CYP450 3A4 inhibitors that are also substrates of the isoenzyme, such as azole antifungals, macrolides, some calcium channel blockers, mifepristone, and nefazodone.', NULL, '-', NULL, '-', 'Others', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338558, 'Fosaprepitant', 'Bicalutamide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338559, 'Fosaprepitant', 'Bortezomib', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of chemotherapeutic agents that are primarily metabolized by CYP450 3A4. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant. In general, the effect of aprepitant on the pharmacokinetics of CYP450 3A4 substrates is expected to be greater when the substrates are administered orally as opposed to intravenously and may be altered following prolonged administration.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials. The potential for increased systemic toxicities of these agents should be considered. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338560, 'Fosaprepitant', 'Bosentan', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St.', NULL, 'The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St. John''s wort. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338561, 'Fosaprepitant', 'Bosutinib', 'Major', 'Coadministration with potent and moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of bosutinib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of bosutinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of bosutinib with potent or moderate CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of bosutinib during and for 2 weeks after treatment with itraconazole. If use of a potent or moderate CYP450 3A4 inhibitor is required, an interruption or a dosage reduction of bosutinib therapy should be considered.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338562, 'Fosaprepitant', 'Brexpiprazole', 'Major', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these isoenzymes.', NULL, 'The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors.', NULL, 'The manufacturer recommends that the brexpiprazole dosage be reduced as follows during concomitant administration of CYP450 inhibitors. The brexpiprazole dosage should be increased to the original level if these agents are discontinued. It is advisable to monitor patients for clinical response.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338563, 'Fosaprepitant', 'Brigatinib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of brigatinib, which is partially metabolized by the isoenzyme.', NULL, 'Concomitant use of moderate CYP450 3A4 inhibitors should generally be avoided during therapy with brigatinib.', NULL, 'Concomitant use of moderate CYP450 3A4 inhibitors should generally be avoided during therapy with brigatinib. If coadministration is required, the brigatinib dose should be reduced by approximately 40% (i.e., from 180 mg to 120 mg, 120 mg to 90 mg, or from 90 mg to 60 mg). There are authorities (AU and UK) that state that no dose adjustment is required, however, patients should be closely monitored. Patients should be monitored for increased brigatinib adverse reactions such as nausea, vomiting, diarrhea, hypertension, bradycardia, hyperglycaemia, visual disturbances, lymphopenia, anemia, and elevations in pancreatic enzymes and creatine phosphokinase. If a dose adjustment is made, the brigatinib dose that was tolerated previously may be resumed following discontinuation of the CYP450 3A4 inhibitor.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338564, 'Fosaprepitant', 'Budesonide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic metabolism via intestinal and hepatic CYP450 3A4. In pharmacokinetic studies, 6- to 8-fold increases in budesonide systemic exposure (AUC) have been observed during coadministration of the potent CYP450 3A4 inhibitor ketoconazole with different oral formulations of budesonide.', NULL, 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors.', NULL, 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors. If concomitant use cannot be avoided, the dosing times between budesonide and the CYP450 3A4 inhibitor should be separated by as much as possible. In addition, the lowest effective dosage of budesonide should be prescribed, and further adjustments made as necessary according to therapeutic response and tolerance.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338565, 'Fosaprepitant', 'Budesonide (nasal)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic metabolism via intestinal and hepatic CYP450 3A4. In pharmacokinetic studies, 6- to 8-fold increases in budesonide systemic exposure (AUC) have been observed during coadministration of the potent CYP450 3A4 inhibitor ketoconazole with different oral formulations of budesonide.', NULL, 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors.', NULL, 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors. If concomitant use cannot be avoided, the dosing times between budesonide and the CYP450 3A4 inhibitor should be separated by as much as possible. In addition, the lowest effective dosage of budesonide should be prescribed, and further adjustments made as necessary according to therapeutic response and tolerance.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338566, 'Fosaprepitant', 'Bupivacaine', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338567, 'Fosaprepitant', 'Buprenorphine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of buprenorphine, which is partially metabolized (approximately 30%) by the isoenzyme.', NULL, 'Caution is advised if buprenorphine is prescribed with CYP450 3A4 inhibitors.', NULL, 'Caution is advised if buprenorphine is prescribed with CYP450 3A4 inhibitors. Induction with buprenorphine should begin at a reduced dosage, and dosage escalation should occur more slowly to allow for assessment of opiate effects and development of patient tolerance. In patients who are already stabilized on buprenorphine, pharmacologic response and vital signs should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the buprenorphine dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338568, 'Fosaprepitant', 'Buspirone', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338569, 'Fosaprepitant', 'Busulfan', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of chemotherapeutic agents that are primarily metabolized by CYP450 3A4. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant. In general, the effect of aprepitant on the pharmacokinetics of CYP450 3A4 substrates is expected to be greater when the substrates are administered orally as opposed to intravenously and may be altered following prolonged administration.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials. The potential for increased systemic toxicities of these agents should be considered. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338570, 'Fosaprepitant', 'Butorphanol', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of butorphanol according to the product labeling. Increased butorphanol concentrations could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Conversely, discontinuation of a CYP450 3A4 inhibitor could decrease butorphanol plasma concentrations, decrease opioid efficacy, and possibly even lead to a withdrawal syndrome in patients who had developed physical dependence to butorphanol.', NULL, 'Patients receiving butorphanol with potent or moderate CYP450 3A4 inhibitors should be carefully monitored, and dosage adjustments made accordingly as needed.', NULL, 'Patients receiving butorphanol with potent or moderate CYP450 3A4 inhibitors should be carefully monitored, and dosage adjustments made accordingly as needed. Patients and/or their caregivers should be advised to seek medical attention if potential signs and symptoms of toxicity occur, such as dizziness, confusion, fainting, extreme sedation, unresponsiveness, bradycardia, slow or difficult breathing, and shortness of breath. When discontinuing CYP450 3A4 inhibitors, monitor patients closely at frequent intervals and consider increasing the opioid dosage if needed to maintain adequate analgesia or if symptoms of opioid withdrawal occur.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338571, 'Fosaprepitant', 'Cabazitaxel', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of chemotherapeutic agents that are primarily metabolized by CYP450 3A4. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant. In general, the effect of aprepitant on the pharmacokinetics of CYP450 3A4 substrates is expected to be greater when the substrates are administered orally as opposed to intravenously and may be altered following prolonged administration.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials. The potential for increased systemic toxicities of these agents should be considered. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338572, 'Fosaprepitant', 'Cabozantinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme.', NULL, 'Caution is advised if cabozantinib is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if cabozantinib is used with moderate CYP450 3A4 inhibitors. Patients should be monitored for potentially increased side effects such as nausea, vomiting, diarrhea, anorexia, weight loss, stomatitis, gastrointestinal perforations and fistulas, palmar-plantar erythrodysesthesia syndrome, hemorrhage, wound complications, hypertension, neutropenia, and thrombocytopenia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338573, 'Fosaprepitant', 'Cannabidiol', 'Minor', 'Cannabidiol is a substrate for CYP450 3A4 and CYP450 2C19. Cannabidiol is metabolized in the liver and the gut (primarily in the liver) by CYP450 2C19 and CYP450 3A4 enzymes, and UGT1A7, UGT1A9, and UGT2B7 isoforms.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338574, 'Fosaprepitant', 'Capmatinib', 'Moderate', 'Coadministration of capmatinib with moderate CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung disease, pneumonitis, and hepatotoxicity. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4, which is one of the primary enzymes responsible for the metabolic clearance of capmatinib.', NULL, 'Close monitoring is recommended whenever capmatinib is used with a moderate CYP450 3A4 inhibitor.', NULL, 'Close monitoring is recommended whenever capmatinib is used with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy with capmatinib, and the dosage adjusted as necessary based on clinical response and toxicity. Patients should be monitored for the development of adverse effects.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338575, 'Fosaprepitant', 'Carbamazepine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St.', NULL, 'The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St. John''s wort. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338576, 'Fosaprepitant', 'Cariprazine', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of cariprazine and its major active metabolite, didesmethyl cariprazine (DDCAR), both of which are primarily metabolized by the isoenzyme.', NULL, 'Caution is advised when cariprazine is prescribed with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised when cariprazine is prescribed with moderate CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as extrapyramidal symptoms, cognitive and motor impairment, hyperglycemia, dyslipidemia, weight gain, orthostatic hypotension, leukopenia, neutropenia, seizures and dysphagia, and the dosage of cariprazine adjusted as necessary in accordance with the product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338577, 'Fosaprepitant', 'Celecoxib', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 2C9. The mechanism is accelerated clearance due to induction of CYP450 2C9 activity by aprepitant.', NULL, 'Caution is advised if aprepitant or fosaprepitant must be used concomitantly with medications that undergo metabolism by CYP450 2C9, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if aprepitant or fosaprepitant must be used concomitantly with medications that undergo metabolism by CYP450 2C9, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338578, 'Fosaprepitant', 'Cenobamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St.', NULL, 'The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St. John''s wort. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338579, 'Fosaprepitant', 'Ceritinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death. Other, more common side effects such as diarrhea, nausea, vomiting, abdominal pain, hyperglycemia, and bradycardia may also increase.', NULL, 'Caution is advised if ceritinib is prescribed with CYP450 3A4 inhibitors.', NULL, 'Caution is advised if ceritinib is prescribed with CYP450 3A4 inhibitors. Pharmacologic response to ceritinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the ceritinib dosage adjusted as necessary. Patients should have periodic ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 500 msec on at least two separate ECGs will require suspension of ceritinib therapy and immediate action to correct any concomitant risk factors before resuming treatment with a 150 mg dosage reduction. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Following discontinuation of the CYP450 3A4 inhibitor, ceritinib therapy should be resumed at the dosage that was taken prior to initiating the CYP450 3A4 inhibitor if an adjustment was made.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338580, 'Fosaprepitant', 'Cevimeline', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338581, 'Fosaprepitant', 'Chloramphenicol', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338582, 'Fosaprepitant', 'Chloroquine', 'Moderate', 'Coadministration with moderate or strong inhibitors of CYP450 2C8 or CYP450 3A4 may increase the plasma concentration of hydroxychloroquine and the risk of toxicities such as QT interval prolongation and ventricular arrhythmias.', NULL, 'Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a moderate or strong CYP450 3A4 or 2C8 inhibitor.', NULL, 'Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a moderate or strong CYP450 3A4 or 2C8 inhibitor. Clinical and laboratory monitoring should be considered whenever a moderate or strong CYP450 3A4 or 2C8 inhibitor is added to or withdrawn from therapy with hydroxychloroquine or chloroquine, and the dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338583, 'Fosaprepitant', 'Cilostazol', 'Major', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active metabolites, which are substrates of these isoenzymes. The possibility of prolonged and/or increased pharmacologic effects of cilostazol should be considered.', NULL, 'A 50% dosage reduction of cilostazol (i.', NULL, 'A 50% dosage reduction of cilostazol (i.e., 50 mg twice a day) should be considered when used with potent or moderate CYP450 3A4 and/or 2C19 inhibitors. Close clinical and laboratory monitoring is advised whenever the inhibitor is added to or withdrawn from therapy, and the cilostazol dosage adjusted as necessary. Patients should be advised to contact their physician if they experience adverse effects of cilostazol such as dizziness, nausea, diarrhea, bleeding, or irregular heartbeat.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338584, 'Fosaprepitant', 'Cimetidine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338585, 'Fosaprepitant', 'Ciprofloxacin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338586, 'Fosaprepitant', 'Citalopram', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338587, 'Fosaprepitant', 'Clarithromycin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338588, 'Fosaprepitant', 'Clobazam', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of benzodiazepines that are metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4. The potential for increased pharmacologic effects of the benzodiazepine, including central nervous system and respiratory depression, should be considered. The interaction is not expected to occur with lorazepam, oxazepam or temazepam, which are primarily metabolized via glucuronidation. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338589, 'Fosaprepitant', 'Clonazepam', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of benzodiazepines that are metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4. The potential for increased pharmacologic effects of the benzodiazepine, including central nervous system and respiratory depression, should be considered. The interaction is not expected to occur with lorazepam, oxazepam or temazepam, which are primarily metabolized via glucuronidation. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338590, 'Fosaprepitant', 'Clorazepic acid', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of benzodiazepines that are metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4. The potential for increased pharmacologic effects of the benzodiazepine, including central nervous system and respiratory depression, should be considered. The interaction is not expected to occur with lorazepam, oxazepam or temazepam, which are primarily metabolized via glucuronidation. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338591, 'Fosaprepitant', 'Cobicistat', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338592, 'Fosaprepitant', 'Cobimetinib', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cobimetinib, which is primarily metabolized by the isoenzyme. The risk and/or severity of adverse effects such as diarrhea, nausea, vomiting, stomatitis, hemorrhage, cardiomyopathy, rash, photosensitivity, retinopathy, retinal vein occlusion, liver enzyme abnormalities, and rhabdomyolysis may be increased.', NULL, 'Concomitant use of cobimetinib with moderate CYP450 3A4 inhibitors should be avoided whenever possible.', NULL, 'Concomitant use of cobimetinib with moderate CYP450 3A4 inhibitors should be avoided whenever possible. If short-term (14 days or less) use of a moderate CYP450 3A4 inhibitor is required during treatment with cobimetinib 60 mg once daily, the manufacturer suggests reducing the cobimetinib dose to 20 mg. Following discontinuation of the moderate CYP450 3A4 inhibitor, the previous dose of 60 mg may be resumed. An alternative to the moderate CYP450 3A4 inhibitor should be used in patients who are already taking a reduced dose of cobimetinib (40 or 20 mg daily).', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338593, 'Fosaprepitant', 'Cocaine (topical)', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338594, 'Fosaprepitant', 'Colchicine', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may significantly increase the serum concentrations of colchicine, which is primarily metabolized by the isoenzyme. Clinical toxicity including myopathy, neuropathy, multiorgan failure, and pancytopenia may occur.', NULL, 'Caution is advised if colchicine is prescribed in combination with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if colchicine is prescribed in combination with moderate CYP450 3A4 inhibitors. In patients with normal renal and hepatic function, the dosage of colchicine should be reduced when used with moderate CYP450 3A4 inhibitors or within 14 days of using them. For the treatment of acute gout flares, the adjusted dosage recommended is 1.2 mg for one dose. Administration should not be repeated for at least three days. For the prophylaxis of gout flares, the adjusted dosage should be 0.3 mg twice a day (or 0.6 mg once a day) if the original regimen was 0.6 mg twice a day, and 0.3 mg once a day if the original regimen was 0.6 once a day. For the treatment of familial Mediterranean fever, the maximum dosage of colchicine is 1.2 mg/day (may be given as 0.6 mg twice a day) when used in the presence of moderate CYP450 3A4 inhibitors. Other significant inhibitors of CYP450 3A4 include amiodarone, dronedarone, imatinib, posaconazole, and quinupristin-dalfopristin, although the extent to which they may interact with colchicine is unknown. A similar dosage adjustment may be required. Patients should be advised to contact their physician if they experience symptoms of toxicity such as abdominal pain, nausea, vomiting, diarrhea, fatigue, myalgia, asthenia, hyporeflexia, paresthesia, and numbness.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338595, 'Fosaprepitant', 'Conivaptan', 'Moderate', 'Coadministration with conivaptan may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by conivaptan.', NULL, 'Caution is advised if conivaptan must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if conivaptan must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever conivaptan is added to or withdrawn from therapy, or the combination avoided altogether.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338596, 'Fosaprepitant', 'Crizotinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338597, 'Fosaprepitant', 'Cyclobenzaprine', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338598, 'Fosaprepitant', 'Cyclophosphamide', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of chemotherapeutic agents that are primarily metabolized by CYP450 3A4. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant. In general, the effect of aprepitant on the pharmacokinetics of CYP450 3A4 substrates is expected to be greater when the substrates are administered orally as opposed to intravenously and may be altered following prolonged administration.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials. The potential for increased systemic toxicities of these agents should be considered. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338599, 'Fosaprepitant', 'Cyclosporine', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338600, 'Fosaprepitant', 'Dabrafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St.', NULL, 'The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St. John''s wort. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338601, 'Fosaprepitant', 'Daclatasvir', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of daclatasvir, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required.', NULL, 'Caution is advised when daclatasvir is used with moderate CYP450 3A4 inhibitors; however, according to the manufacturer, dose adjustments are not required. Patients should be monitored for adverse effects such as headache, fatigue, nausea, diarrhea, and serum lipase elevations.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338602, 'Fosaprepitant', 'Darifenacin', 'Moderate', 'Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes.', NULL, 'Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary.', NULL, 'Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary. Patients should be advised to contact their physician if they experience undue adverse effects of darifenacin such as severe abdominal pain or constipation for 3 or more days.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338603, 'Fosaprepitant', 'Darolutamide', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of darolutamide, which is a substrate of both the isoenzyme and the efflux transporter. Caution is advised when darolutamide is used with CYP450 3A4 or P-gp inhibitors. Patients should be monitored more frequently for adverse effects such as fatigue, hypertension, neutropenia and abnormal liver function tests, and the darolutamide dosage adjusted as necessary in accordance with the product labeling.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338604, 'Fosaprepitant', 'Darunavir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338605, 'Fosaprepitant', 'Dasatinib', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of chemotherapeutic agents that are primarily metabolized by CYP450 3A4. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant. In general, the effect of aprepitant on the pharmacokinetics of CYP450 3A4 substrates is expected to be greater when the substrates are administered orally as opposed to intravenously and may be altered following prolonged administration.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials. The potential for increased systemic toxicities of these agents should be considered. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338606, 'Fosaprepitant', 'Deferasirox', 'Moderate', 'Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism may involve induction of CYP450 3A4 activity by deferasirox, although in vitro, the drug has been shown to inhibit CYP450 3A4.', NULL, 'Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever deferasirox is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338607, 'Fosaprepitant', 'Deflazacort', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of 21-desdeflazacort, the active metabolite of deflazacort that is formed by esterases after oral administration and further metabolized by CYP450 3A4 to several inactive metabolites.', NULL, 'The manufacturer suggests using one-third of the recommended dosage of deflazacort when coadministered with potent or moderate CYP450 3A4 inhibitors.', NULL, 'The manufacturer suggests using one-third of the recommended dosage of deflazacort when coadministered with potent or moderate CYP450 3A4 inhibitors. Some authorities recommend avoiding concomitant use of deflazacort and CYP450 3A inhibitors unless the benefit outweighs the risk, in which case patients should be monitored for systemic corticosteroid side effects.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338608, 'Fosaprepitant', 'Delavirdine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338609, 'Fosaprepitant', 'Diazepam', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of benzodiazepines that are metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4. The potential for increased pharmacologic effects of the benzodiazepine, including central nervous system and respiratory depression, should be considered. The interaction is not expected to occur with lorazepam, oxazepam or temazepam, which are primarily metabolized via glucuronidation. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338610, 'Fosaprepitant', 'Dihydroergotamine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', NULL, 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338611, 'Fosaprepitant', 'Disopyramide', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338612, 'Fosaprepitant', 'Docetaxel', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 or dual CYP450 3A4 and P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of docetaxel, which is a substrate of both CYP450 3A4 and P-gp.', NULL, 'Caution is advised if docetaxel is prescribed in combination with CYP450 3A4 inhibitors or dual CYP450 3A4 and P-gp inhibitors.', NULL, 'Caution is advised if docetaxel is prescribed in combination with CYP450 3A4 inhibitors or dual CYP450 3A4 and P-gp inhibitors. Patients should be closely monitored for the development of docetaxel toxicity such as myelosuppression, stomatitis, neurotoxicity (e.g., paresthesia, dysesthesia, pain), myalgia, asthenia, fluid retention, nausea, vomiting, and diarrhea. Dosage reduction of docetaxel may be required if an interaction is suspected.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338613, 'Fosaprepitant', 'Dofetilide', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338614, 'Fosaprepitant', 'Donepezil', 'Minor', 'Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of donepezil, which is primarily metabolized by these isoenzymes.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338615, 'Fosaprepitant', 'Doravirine', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme.', NULL, '-', NULL, '-', 'Metabolism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338616, 'Fosaprepitant', 'Doxorubicin', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of chemotherapeutic agents that are primarily metabolized by CYP450 3A4. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant. In general, the effect of aprepitant on the pharmacokinetics of CYP450 3A4 substrates is expected to be greater when the substrates are administered orally as opposed to intravenously and may be altered following prolonged administration.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials.', NULL, 'Caution is advised if aprepitant or fosaprepitant is administered with chemotherapeutic agents that are primarily metabolized by CYP450 3A4, particularly those that were not studied extensively in premarketing trials. The potential for increased systemic toxicities of these agents should be considered. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338617, 'Fosaprepitant', 'Dronabinol', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 2C9. The mechanism is accelerated clearance due to induction of CYP450 2C9 activity by aprepitant.', NULL, 'Caution is advised if aprepitant or fosaprepitant must be used concomitantly with medications that undergo metabolism by CYP450 2C9, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if aprepitant or fosaprepitant must be used concomitantly with medications that undergo metabolism by CYP450 2C9, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338618, 'Fosaprepitant', 'Dronedarone', 'Moderate', 'Coadministration of dronedarone with a drug that is both a substrate as well as inhibitor of CYP450 3A4 may result in increased plasma concentrations of both drugs. Dronedarone itself is also a substrate and moderate inhibitor of CYP450 3A4. Theoretically, competitive and/or noncompetitive metabolic inhibition may occur. Because dronedarone is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.', NULL, 'Caution is advised if dronedarone is prescribed in combination with a drug that is an inhibitor of CYP450 3A4.', NULL, 'Caution is advised if dronedarone is prescribed in combination with a drug that is an inhibitor of CYP450 3A4. Pharmacologic response to dronedarone should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate dronedarone toxicity such as excessive fatigue, fainting, difficulty breathing, chest pain or tightness, bradycardia, or symptoms of torsade de pointes such as dizziness, palpitations, irregular heartbeat, shortness of breath, and syncope. Likewise, clinical and/or laboratory monitoring may be appropriate for the coadministered drug following the addition or withdrawal of dronedarone, and the dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338619, 'Fosaprepitant', 'Drospirenone', 'Moderate', 'RECOMMENDED: Aprepitant and its prodrug, fosaprepitant, may reduce the efficacy of low-dose hormonal contraceptives during and for up to 28 days after treatment. The proposed mechanism is aprepitant induction of CYP450 3A4, the isoenzyme partially responsible for the metabolic clearance of contraceptive hormones.', NULL, 'Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with aprepitant or fosaprepitant.', NULL, 'Women using low-dose hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with aprepitant or fosaprepitant. Alternative or additional methods of birth control is recommended during treatment with aprepitant and for one month following the last dose of aprepitant. Data are not available for single-dosing of aprepitant 40 mg. However, since the timing of aprepitant administration relative to ovulation could cause contraceptive failure, the same precaution as for the 125 mg/80 mg regimen should be observed. Intrauterine systems are unlikely to be significantly affected because of their local action. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338620, 'Fosaprepitant', 'Dutasteride', 'Moderate', 'Based on in vitro data, coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of dutasteride, which is metabolized by the isoenzyme.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of dutasteride should be considered during concomitant therapy with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of dutasteride should be considered during concomitant therapy with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338621, 'Fosaprepitant', 'Duvelisib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of duvelisib, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised when duvelisib is used with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when duvelisib is used with CYP450 3A4 inhibitors. Patients should be monitored for the development of toxicities such as diarrhea, colitis, neutropenia, thrombocytopenia, pneumonitis, infections, cutaneous reactions and hepatotoxicity, and the dosing adjusted or discontinued in accordance with the duvelisib product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338622, 'Fosaprepitant', 'Efavirenz', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St.', NULL, 'The possibility of diminished therapeutic response to aprepitant should be considered during coadministration with CYP450 3A4 inducers, particularly potent ones like carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifampin, and St. John''s wort. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338623, 'Fosaprepitant', 'Elagolix', 'Moderate', 'Coadministration with inhibitors of the OATP 1B1 hepatic uptake transporter, CYP450 3A4 metabolic isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of elagolix. The effect of P-gp inhibitors on the pharmacokinetics of elagolix has not been studied, but some increases in elagolix exposure may occur, as it is a P-gp substrate. Increased exposure to elagolix may increase the risk of serious adverse effects such as bone loss, suicidal ideation and behavior, exacerbation of mood disorders, and hepatic transaminase elevations.', NULL, 'Caution is advised when elagolix is used with OATP 1B1, CYP450 3A4, and/or P-gp inhibitors.', NULL, 'Caution is advised when elagolix is used with OATP 1B1, CYP450 3A4, and/or P-gp inhibitors. Patients should be monitored for potentially altered effects of elagolix following the initiation or discontinuation of these inhibitors, and the elagolix dosage adjusted as necessary.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338624, 'Fosaprepitant', 'Eletriptan', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eletriptan, which is primarily metabolized by the isoenzyme.', NULL, 'Eletriptan should not be used within at least 72 hours of treatment with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, nefazodone, delavirdine, most protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, 'Eletriptan should not be used within at least 72 hours of treatment with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, nefazodone, delavirdine, most protease inhibitors, and ketolide and certain macrolide antibiotics. Patients should have vital signs monitored regularly and advised to notify their physician if they experience signs and symptoms of vasospasm such as numbness, tingling, or cyanosis in the extremities; muscle pains; weakness; or chest pain or tightness. Alternatively, other 5-HT1 receptor agonists that are not metabolized by CYP450 3A4 may be considered, such as frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338625, 'Fosaprepitant', 'Eliglustat', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.', NULL, 'The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs).', NULL, 'The use of eliglustat in combination with one or more drugs that may result in moderate inhibition of CYP450 3A4 and moderate to potent inhibition of CYP450 2D6 is considered contraindicated in CYP450 2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs). In the absence of a concomitant CYP450 2D6 inhibitor, eliglustat may be prescribed at a reduced dosage of 84 mg once daily to EMs treated with a moderate CYP450 3A4 inhibitor. However, eliglustat should not be used with a moderate CYP450 3A4 inhibitor in CYP450 2D6 IMs or poor metabolizers (PMs). Moderate CYP450 3A4 inhibitors include aprepitant, ciprofloxacin, clotrimazole, crizotinib, darunavir, diltiazem, dronedarone, fluconazole, fusidic acid, imatinib, isavuconazonium, miconazole, mifepristone, netupitant, quinupristin-dalfopristin, ranolazine, stiripentol, and verapamil. Potent and moderate CYP450 2D6 inhibitors include abiraterone, bupropion, celecoxib, cimetidine, cinacalcet, clobazam, darifenacin, diphenhydramine, duloxetine, fluoxetine, methotrimeprazine, mirabegron, paroxetine, propoxyphene, quinidine, ranolazine, sertraline, stiripentol, and terbinafine.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338626, 'Fosaprepitant', 'Encorafenib', 'Major', 'Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of encorafenib, which is primarily metabolized by the isoenzyme. Increased exposure to encorafenib may increase the risk of serious and life-threatening adverse effects such as hemorrhage, uveitis, QT prolongation, hepatotoxicity, dermatologic reactions, and new malignancies.', NULL, 'Concomitant use of encorafenib with moderate CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of encorafenib with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the encorafenib dose to one-half of the dose used prior to addition of the moderate CYP450 3A4 inhibitor. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, the encorafenib dose that was taken prior to initiating the inhibitor may be resumed.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338627, 'Fosaprepitant', 'Enfortumab vedotin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of enfortumab vedotin. Enfortumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when enfortumab vedotin is used concomitantly with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when enfortumab vedotin is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, hyperglycaemia, dermatologic reactions (maculopapular rash, pruritus, symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), bullous dermatitis, exfoliative dermatitis, palmar-plantar erythrodysesthesia), and ocular disorders (dry eyes, keratitis, blurred vision, limbal stem cell deficiency), and the dosing of enfortumab vedotin adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338628, 'Fosaprepitant', 'Methadone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of methadone, which is metabolized primarily by CYP450 3A4, 2B6, 2C19, and to a lesser extent by CYP450 2C9 and 2D6. The possibility of prolonged and/or increased pharmacologic effects of methadone, such as central nervous system and respiratory depression, should be considered. In addition, high dosages (particularly above 200 mg/day) and serum levels of methadone have been associated with QT interval prolongation and torsade de pointes arrhythmia.', NULL, 'Caution is advised if methadone is prescribed in combination with CYP450 3A4 inhibitors.', NULL, 'Caution is advised if methadone is prescribed in combination with CYP450 3A4 inhibitors. Pharmacologic response to methadone should be closely monitored and the dosage adjusted accordingly, particularly following initiation or discontinuation of the CYP450 3A4 inhibitor in patients who are stabilized on their methadone regimen. Patients should be advised to report excessive drowsiness, nausea, or asthenia to their physician, and to seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. ECG monitoring should be considered for patients on methadone with heart or liver disease; conduction abnormalities; electrolyte disturbances (i.e., hypokalemia, hypomagnesemia); concomitant use of drugs that may cause QT prolongation or electrolyte loss; concomitant use of CYP450 3A4 inhibitors; or use of methadone at dosages greater than 200 mg daily.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338629, 'Foscarnet', 'Alfuzosin', 'Moderate', 'Alfuzosin may cause modest prolongation of the QTc interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if alfuzosin is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if alfuzosin is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If taking drugs that also cause CNS or orthostatic effects (e.g., psychotropic drugs like tricyclic antidepressants, phenothiazines, and neuroleptics), patients should be made aware of the possibility of additive effects with alfuzosin and counseled to avoid activities requiring mental alertness until they know how these agents affect them.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338630, 'Foscarnet', 'Amifampridine', 'Moderate', 'The use of amifampridine is associated with a dose-related risk of seizures, and the risk may be further increased when coadministered with other drugs that can reduce the seizure threshold such as antidepressants, antimalarials, neuroleptics, phenothiazines, and quinolones.', NULL, 'Caution is advised if amifampridine is coadministered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with other risk factors for seizures (e.', NULL, 'Caution is advised if amifampridine is coadministered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with other risk factors for seizures (e.g., head trauma; brain tumor; severe hepatic cirrhosis; metabolic disorders; CNS infections; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; diabetes treated with oral hypoglycemic agents or insulin).', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338631, 'Foscarnet', 'Amifostine', 'Moderate', 'Coadministration with other drugs that can reduce serum calcium may potentiate the risk of hypocalcemia associated with foscarnet. Foscarnet chelates with divalent metal ions and causes a dose-related reduction in ionized serum calcium.', NULL, 'Close monitoring is recommended during concomitant use of foscarnet with other drugs that are known to affect calcium concentrations.', NULL, 'Close monitoring is recommended during concomitant use of foscarnet with other drugs that are known to affect calcium concentrations. Serum creatinine and electrolyte levels should be assessed prior to initiating therapy and frequently during therapy. Patients should be advised to promptly notify their physician if they experience potential symptoms of hypocalcemia such as perioral tingling, numbness in extremities, and paresthesias.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338632, 'Foscarnet', 'Amikacin', 'Major', 'The potential nephrotoxicity of foscarnet and aminoglycosides may be additive. Concomitant use of these drugs could also lead to additive hypokalemia, hypomagnesemia, and hypocalcemia, which may increase the foscarnet-related risks of QT prolongation and seizures.', NULL, 'The manufacturer recommends avoiding concomitant therapy unless the potential benefits outweigh the risks.', NULL, 'The manufacturer recommends avoiding concomitant therapy unless the potential benefits outweigh the risks. Electrolyte levels and renal function of patients receiving these medications concomitantly should be monitored carefully, and dosages adjusted or discontinued if necessary.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338633, 'Foscarnet', 'Amiodarone', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338634, 'Amisulpride', 'Foscarnet', 'Major', 'Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution and close clinical monitoring (e.', NULL, 'Caution and close clinical monitoring (e.g., electrocardiogram, serum electrolytes) are recommended if amisulpride is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338635, 'Amitriptyline', 'Foscarnet', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338636, 'Amphotericin B', 'Foscarnet', 'Major', 'The potential nephrotoxicity of foscarnet and amphotericin B may be additive. Concomitant use of these drugs could also lead to additive hypokalemia, hypomagnesemia, and hypocalcemia, which may increase the foscarnet-related risks of QT prolongation and seizures.', NULL, 'The manufacturer recommends avoiding concomitant therapy unless the potential benefits outweigh the risks.', NULL, 'The manufacturer recommends avoiding concomitant therapy unless the potential benefits outweigh the risks. Electrolyte levels and renal function of patients receiving these medications concomitantly should be monitored carefully, and dosages adjusted or discontinued if necessary.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338637, 'Amphotericin B (lipid complex)', 'Foscarnet', 'Major', 'The potential nephrotoxicity of foscarnet and amphotericin B may be additive. Concomitant use of these drugs could also lead to additive hypokalemia, hypomagnesemia, and hypocalcemia, which may increase the foscarnet-related risks of QT prolongation and seizures.', NULL, 'The manufacturer recommends avoiding concomitant therapy unless the potential benefits outweigh the risks.', NULL, 'The manufacturer recommends avoiding concomitant therapy unless the potential benefits outweigh the risks. Electrolyte levels and renal function of patients receiving these medications concomitantly should be monitored carefully, and dosages adjusted or discontinued if necessary.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338638, 'Anagrelide', 'Foscarnet', 'Major', 'Anagrelide can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of anagrelide with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of anagrelide with other drugs that can prolong the QT interval should generally be avoided. Patients receiving anagrelide should have a cardiovascular examination, including an ECG, prior to initiation of treatment and monitored for cardiovascular effects during treatment. Hypokalemia or hypomagnesemia must be corrected prior to therapy and electrolytes monitored periodically during therapy.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338639, 'Foscarnet', 'Apalutamide', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338640, 'Foscarnet', 'Apomorphine', 'Moderate', 'Apomorphine may cause modest prolongation of the QTc interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if apomorphine is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if apomorphine is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. If taking drugs that also cause CNS or orthostatic effects (e.g., psychotropic drugs like tricyclic antidepressants, phenothiazines, and neuroleptics), patients should be made aware of the possibility of additive effects with apomorphine and counseled to avoid activities requiring mental alertness until they know how these agents affect them.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338641, 'Foscarnet', 'Arformoterol', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338642, 'Foscarnet', 'Aripiprazole', 'Moderate', 'It is uncertain whether aripiprazole causes clinically significant prolongation of the QT interval.', NULL, 'Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation.', NULL, 'Some authorities recommend caution when aripiprazole is used with drugs that are known to cause QT prolongation. ECG monitoring may be advisable in some cases, such as in patients with a history of cardiac arrhythmias or congenital or family history of long QT syndrome. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338643, 'Foscarnet', 'Arsenic trioxide', 'Major', 'Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'If possible, medications that are known to prolong the QT interval should be discontinued prior to initiating therapy with arsenic trioxide and withheld for at least several weeks after completion of therapy.', NULL, 'If possible, medications that are known to prolong the QT interval should be discontinued prior to initiating therapy with arsenic trioxide and withheld for at least several weeks after completion of therapy. Caution is advised if concomitant use cannot be avoided. Patients should have frequent ECGs and be monitored for arrhythmias when QT interval is prolonged. An absolute QT interval exceeding 500 msec will require immediate action to correct concomitant risk factors, if any, as well as a thorough assessment of the need for continued therapy. Patients who develop syncope or arrhythmia should be hospitalized for clinical and laboratory monitoring.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338644, 'Foscarnet', 'Asenapine', 'Moderate', 'Asenapine may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of asenapine with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of asenapine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338645, 'Foscarnet', 'Atomoxetine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338646, 'Foscarnet', 'Azithromycin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338647, 'Foscarnet', 'Balsalazide', 'Moderate', 'Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of 5-aminosalicylate or its prodrugs has been associated with rare reports of renal impairment including minimal change nephropathy, acute and chronic interstitial nephritis, and renal failure.', NULL, 'Caution is advised when 5-aminosalicylate preparations are prescribed to patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised when 5-aminosalicylate preparations are prescribed to patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be evaluated prior to and during 5-aminosalicylate therapy.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338648, 'Foscarnet', 'Beclomethasone dipropionate', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338649, 'Foscarnet', 'Betamethasone', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338650, 'Foscarnet', 'Bicalutamide', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338651, 'Foscarnet', 'Bisacodyl', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', NULL, 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338652, 'Foscarnet', 'Bosutinib', 'Moderate', 'Bosutinib may cause QTc prolongation without associated arrhythmia. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if bosutinib is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if bosutinib is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338653, 'Human botulinum neurotoxin A/B immune globulin', 'Foscarnet', 'Major', 'Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338654, 'Foscarnet', 'Bumetanide', 'Moderate', 'Coadministration with other drugs that can reduce serum calcium may potentiate the risk of hypocalcemia associated with foscarnet. Foscarnet chelates with divalent metal ions and causes a dose-related reduction in ionized serum calcium.', NULL, 'Close monitoring is recommended during concomitant use of foscarnet with other drugs that are known to affect calcium concentrations.', NULL, 'Close monitoring is recommended during concomitant use of foscarnet with other drugs that are known to affect calcium concentrations. Serum creatinine and electrolyte levels should be assessed prior to initiating therapy and frequently during therapy. Patients should be advised to promptly notify their physician if they experience potential symptoms of hypocalcemia such as perioral tingling, numbness in extremities, and paresthesias.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338655, 'Foscarnet', 'Buprenorphine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338656, 'Foscarnet', 'Cabozantinib', 'Major', 'Cabozantinib can cause prolongation of the QT interval.', NULL, 'Caution and close clinical monitoring are recommended if cabozantinib is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution and close clinical monitoring are recommended if cabozantinib is used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338657, 'Foscarnet', 'Salmon calcitonin', 'Moderate', 'Coadministration with other drugs that can reduce serum calcium may potentiate the risk of hypocalcemia associated with foscarnet. Foscarnet chelates with divalent metal ions and causes a dose-related reduction in ionized serum calcium.', NULL, 'Close monitoring is recommended during concomitant use of foscarnet with other drugs that are known to affect calcium concentrations.', NULL, 'Close monitoring is recommended during concomitant use of foscarnet with other drugs that are known to affect calcium concentrations. Serum creatinine and electrolyte levels should be assessed prior to initiating therapy and frequently during therapy. Patients should be advised to promptly notify their physician if they experience potential symptoms of hypocalcemia such as perioral tingling, numbness in extremities, and paresthesias.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338658, 'Foscarnet', 'Ceritinib', 'Major', 'Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if ceritinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting ceritinib therapy and periodically during treatment.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338659, 'Foscarnet', 'Chloroquine', 'Major', 'Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Because COVID-19 may disproportionately affect the elderly and individuals with preexisting heart disease, and cardiac complications such as myocarditis and cardiomyopathy as well as organ failure may occur in patients with severe COVID-19, it appears likely that hospitalized patients with COVID-19 may represent a particularly susceptible and high-risk population, and other, less critically ill patients may not have the same arrhythmic risk.', NULL, 'Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.', NULL, 'Coadministration of chloroquine or hydroxychloroquine with other drugs that can prolong the QT interval should generally be avoided, particularly in patients with baseline QT prolongation (e.g., QTc >=500 msec) or congenital long QT syndrome. Close monitoring of QTc interval, electrolyte levels, and renal and hepatic function is recommended if concomitant use is required and benefits are anticipated to outweigh the risks. Electrolyte abnormalities should be corrected prior to initiating treatment with chloroquine or hydroxychloroquine. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Because chloroquine and hydroxychloroquine are eliminated slowly from the body, the potential for drug interactions should be observed for a prolonged period following their discontinuation.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338660, 'Foscarnet', 'Cidofovir', 'Major', 'Coadministration of cidofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Dose-related nephrotoxicity is the major toxicity of cidofovir. Cases of acute renal failure resulting in dialysis and/or contributing to death have occurred with as few as one or two doses of cidofovir.', NULL, 'Concomitant use of cidofovir with other potentially nephrotoxic agents (e.', NULL, 'Concomitant use of cidofovir with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; aminosalicylates; antiviral/antiretroviral agents such as acyclovir, adefovir, foscarnet, ganciclovir, and tenofovir; antineoplastics such as aldesleukin, cisplatin, clofarabine, ifosfamide, streptozocin, and high intravenous dosages of methotrexate; chelating agents such as deferasirox, deferoxamine, edetate disodium, and edetate calcium disodium; immunosuppressants such as cyclosporine, everolimus, sirolimus, and tacrolimus; intravascular contrast media; intravenous bisphosphonates; intravenous pentamidine; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents; gallium nitrate; lithium; penicillamine) is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338661, 'Foscarnet', 'Ciprofloxacin', 'Moderate', 'Limited data suggest that coadministration of foscarnet and ciprofloxacin may potentiate the risk of seizures. Both agents are individually epileptogenic and may have additive effects when combined. Specifically, foscarnet can decrease the seizure threshold by chelating ionized calcium and magnesium, while ciprofloxacin inhibits gamma-aminobutyric acid (GABA).', NULL, 'Caution is advised during coadministration of foscarnet and ciprofloxacin, particularly in elderly patients and those with renal impairment, electrolyte and metabolic abnormalities, or underlying neurologic disorders.', NULL, 'Caution is advised during coadministration of foscarnet and ciprofloxacin, particularly in elderly patients and those with renal impairment, electrolyte and metabolic abnormalities, or underlying neurologic disorders. The same precaution may be applicable during therapy with other quinolones, although clinical data are lacking.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338662, 'Foscarnet', 'Cisplatin', 'Moderate', 'Coadministration with other drugs that can reduce serum calcium may potentiate the risk of hypocalcemia associated with foscarnet. Foscarnet chelates with divalent metal ions and causes a dose-related reduction in ionized serum calcium.', NULL, 'Close monitoring is recommended during concomitant use of foscarnet with other drugs that are known to affect calcium concentrations.', NULL, 'Close monitoring is recommended during concomitant use of foscarnet with other drugs that are known to affect calcium concentrations. Serum creatinine and electrolyte levels should be assessed prior to initiating therapy and frequently during therapy. Patients should be advised to promptly notify their physician if they experience potential symptoms of hypocalcemia such as perioral tingling, numbness in extremities, and paresthesias.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338663, 'Foscarnet', 'Citalopram', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', NULL, 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338664, 'Foscarnet', 'Clarithromycin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338665, 'Foscarnet', 'Clofarabine', 'Moderate', 'Coadministration of clofarabine with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Moreover, renal impairment secondary to the use of these agents may reduce the clearance of clofarabine, which is primarily eliminated by renal excretion. This may increase the risk of other adverse effects such as nausea, vomiting, stomatitis, hypertension, hypotension, myelosuppression, hemorrhage, and hepatotoxicity.', NULL, 'Drugs that are potentially nephrotoxic (e.', NULL, 'Drugs that are potentially nephrotoxic (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; aminosalicylates; antiviral/antiretroviral agents such as acyclovir, adefovir, cidofovir, foscarnet, ganciclovir, and tenofovir; antineoplastics such as aldesleukin, carboplatin, cisplatin, ifosfamide, streptozocin, and high intravenous dosages of methotrexate; chelating agents such as deferasirox, deferoxamine, edetate disodium, and edetate calcium disodium; immunosuppressants such as cyclosporine, everolimus, sirolimus, and tacrolimus; intravenous bisphosphonates; intravenous pentamidine; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents; gallium nitrate; lithium; penicillamine) should be avoided during the 5 days of clofarabine administration if possible. Renal function should be evaluated prior to and during therapy, and administration discontinued immediately if substantial increases (e.g., grade 3 or higher) in creatinine are noted.', 'Excretion', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338666, 'Foscarnet', 'Clofazimine', 'Moderate', 'Clofazimine may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if clofazimine is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if clofazimine is used in combination with other drugs that can prolong the QT interval. Consider monitoring electrocardiograms, particularly in patients receiving clofazimine dosages greater than 100 mg/day, and discontinue QT-prolonging medications if clinically significant ventricular arrhythmia is noted or if QTcF interval >=500 ms is observed. If syncope occurs, obtain an ECG to detect QT prolongation.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338667, 'Foscarnet', 'Clomipramine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338668, 'Foscarnet', 'Clozapine', 'Major', 'Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Clozapine has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can cause QT prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function, such as antineoplastic, antimalarial, and antirheumatic agents.', NULL, 'Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function, such as antineoplastic, antimalarial, and antirheumatic agents. Caution is recommended if clozapine is used in combination with other drugs that can prolong the QT interval. Serum electrolytes, including potassium, magnesium and calcium, should be measured at baseline and periodically during treatment, and any abnormalities corrected prior to initiating clozapine. Clozapine treatment should be discontinued if the QTc interval exceeds 500 msec. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338669, 'Foscarnet', 'Corticotropin', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338670, 'Foscarnet', 'Tetracosactide', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338671, 'Foscarnet', 'Crizotinib', 'Major', 'Crizotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if crizotinib is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if crizotinib is used in combination with other drugs that can prolong the QT interval. ECG and serum electrolytes, including potassium, magnesium and calcium, should be monitored before starting crizotinib therapy and periodically during treatment.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338672, 'Foscarnet', 'Cyclosporine', 'Major', 'Renal failure risk may be increased in patients on foscarnet and cyclosporine therapy. The mechanism may be due to additive or synergistic nephrotoxicity. In two reported cases, cyclosporine concentrations remained within the therapeutic range and renal function returned to normal after discontinuation of the foscarnet.', NULL, 'The manufacturer recommends avoiding the concurrent use of other nephrotoxic drugs during foscarnet therapy.', NULL, 'The manufacturer recommends avoiding the concurrent use of other nephrotoxic drugs during foscarnet therapy. If these agents are used concomitantly, consider close observation of renal function and discontinue foscarnet treatment if needed.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338673, 'Human cytomegalovirus immune globulin', 'Foscarnet', 'Major', 'Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338674, 'Foscarnet', 'Dasatinib', 'Moderate', 'In vitro data suggest that dasatinib has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if dasatinib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if dasatinib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338675, 'Foscarnet', 'Daunorubicin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338676, 'Foscarnet', 'Deferasirox', 'Major', 'Theoretical concerns exist regarding the potential for increased risk of renal impairment during coadministration of deferasirox with other nephrotoxic agents. The use of deferasirox has been associated with postmarketing reports of acute renal failure, in some cases resulting in dialysis or even fatality.', NULL, 'Caution is advised if deferasirox is used in combination with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised if deferasirox is used in combination with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Serum creatinine and/or creatinine clearance should be closely monitored (e.g., prior to initiation of deferasirox therapy, then weekly during the first month after initiation or modification of therapy and monthly thereafter), especially in the elderly and patients with preexisting renal impairment, comorbid conditions, dehydration, or severe infections. Dosage reduction, interruption, or discontinuation should be considered in the presence of creatinine elevations. A progressive increase in serum creatinine beyond the age-appropriate upper limit of normal may warrant an interruption of therapy. Once the creatinine has returned to within the normal range, therapy may be reinitiated at a lower dose followed by a gradual dose escalation according to the product labeling, provided the clinical benefit is expected to outweigh potential risks.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338677, 'Foscarnet', 'Deflazacort', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', NULL, 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338678, 'Foscarnet', 'Degarelix', 'Moderate', 'Long-term androgen deprivation therapy can prolong the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval.', NULL, 'The benefits of androgen deprivation therapy should be carefully assessed against the potential risk in patients receiving other drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected prior to initiating therapy, and periodic monitoring of electrocardiograms and electrolytes should be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338679, 'Foscarnet', 'Delafloxacin', 'Moderate', 'Limited data suggest that coadministration of foscarnet and ciprofloxacin may potentiate the risk of seizures. Both agents are individually epileptogenic and may have additive effects when combined. Specifically, foscarnet can decrease the seizure threshold by chelating ionized calcium and magnesium, while ciprofloxacin inhibits gamma-aminobutyric acid (GABA).', NULL, 'Caution is advised during coadministration of foscarnet and ciprofloxacin, particularly in elderly patients and those with renal impairment, electrolyte and metabolic abnormalities, or underlying neurologic disorders.', NULL, 'Caution is advised during coadministration of foscarnet and ciprofloxacin, particularly in elderly patients and those with renal impairment, electrolyte and metabolic abnormalities, or underlying neurologic disorders. The same precaution may be applicable during therapy with other quinolones, although clinical data are lacking.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338680, 'Foscarnet', 'Denosumab', 'Moderate', 'Coadministration with other drugs that can reduce serum calcium may potentiate the risk of hypocalcemia associated with foscarnet. Foscarnet chelates with divalent metal ions and causes a dose-related reduction in ionized serum calcium.', NULL, 'Close monitoring is recommended during concomitant use of foscarnet with other drugs that are known to affect calcium concentrations.', NULL, 'Close monitoring is recommended during concomitant use of foscarnet with other drugs that are known to affect calcium concentrations. Serum creatinine and electrolyte levels should be assessed prior to initiating therapy and frequently during therapy. Patients should be advised to promptly notify their physician if they experience potential symptoms of hypocalcemia such as perioral tingling, numbness in extremities, and paresthesias.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338681, 'Foscarnet', 'Desipramine', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338682, 'Foscarnet', 'Deutetrabenazine', 'Moderate', 'Deutetrabenazine has been associated with modest QT interval prolongation. In addition, central nervous system (CNS)-depressant effects may be additively or synergistically increased in patients taking deutetrabenazine with certain other drugs that cause these effects, especially in elderly or debilitated patients.', NULL, 'Coadministration of deutetrabenazine with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of deutetrabenazine with other drugs that can prolong the QT interval should generally be avoided. Deutetrabenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. If concomitant use is required, assessment of baseline QT interval and periodic monitoring during therapy may be considered. In addition, dosage reduction may be considered in patients on concurrent therapy with a strong CYP450 2D6 inhibitor, or in patients who are poor metabolizers of CYP450 2D6.', 'Metabolism, Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338683, 'Foscarnet', 'Dexlansoprazole', 'Moderate', 'Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.', NULL, 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus.', NULL, 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338684, 'Foscarnet', 'Disopyramide', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', NULL, 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338685, 'Foscarnet', 'Dofetilide', 'Major', 'Like other class III antiarrhythmic agents, dofetilide can cause dose-related QT interval prolongation. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of dofetilide with other drugs that can prolong the QT interval has not been studied and is not recommended.', NULL, 'Coadministration of dofetilide with other drugs that can prolong the QT interval has not been studied and is not recommended.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338686, 'Foscarnet', 'Dolasetron', 'Major', 'Dolasetron can cause dose-related prolongation of the QT interval via its pharmacologically active metabolite, hydrodolasetron. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if dolasetron is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if dolasetron is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. ECG monitoring may be appropriate in high-risk patients. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338687, 'Foscarnet', 'Donepezil', 'Moderate', 'Acetylcholinesterase inhibitors may have vagotonic effects on the sinoatrial and atrioventricular nodes, which occasionally manifest as bradycardia or heart block (<2%). Because bradycardia is a risk factor for torsade de pointes, a theoretical risk exists when combined with agents that prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval.', NULL, 'Caution is advised when acetylcholinesterase inhibitors are used with drugs that can prolong the QT interval. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338688, 'Foscarnet', 'Doxepin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338689, 'Foscarnet', 'Doxorubicin', 'Moderate', 'Theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. The risk of an individual agent or a combination of these agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances.', NULL, 'Caution and clinical monitoring are recommended.', NULL, 'Caution and clinical monitoring are recommended. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338690, 'Foscarnet', 'Dronedarone', 'Major', 'Dronedarone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of dronedarone with other drugs that can prolong the QT interval is considered contraindicated.', NULL, 'Coadministration of dronedarone with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338691, 'Foscarnet', 'Droperidol', 'Major', 'The use of droperidol has been associated with QT interval prolongation, torsade de pointes and other serious arrhythmias, and sudden death. The concurrent administration of agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins), drugs known to increase the QT interval (e.g., phenothiazines, tricyclic antidepressants, antiarrhythmic agents, etc.), certain other drugs (benzodiazepines, volatile anesthetics, intravenous opiates), or alcohol abuse may increase the risk of prolonged QT syndrome.', NULL, 'The manufacturer recommends extreme caution if droperidol must be given concomitantly with these agents.', NULL, 'The manufacturer recommends extreme caution if droperidol must be given concomitantly with these agents. The dosage of droperidol should be individualized and titrated to the desired effect. Routine vital sign and ECG monitoring is recommended. When droperidol is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338692, 'Foscarnet', 'Efavirenz', 'Major', 'Efavirenz can cause significant QT interval prolongation in patients with the CYP450 2B6 *6/*6 genotype due to reduced metabolic clearance of the drug stemming from decreased levels of functional CYP450 2B6 isoenzyme.', NULL, 'Alternatives to efavirenz should be considered in patients receiving other drugs that can prolong the QT interval.', NULL, 'Alternatives to efavirenz should be considered in patients receiving other drugs that can prolong the QT interval. Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Metabolism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1338693, 'Foscarnet', 'Encorafenib', 'Moderate', 'Encorafenib may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of encorafenib with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of encorafenib with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Hypokalemia and hypomagnesemia should be corrected prior to initiation of encorafenib treatment, and electrolytes periodically monitored during treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Withhold, reduce dose, or permanently discontinue encorafenib in accordance with the product labeling for QTc exceeding 500 msec.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317475);
